GreenLight Biosciences (GRNA) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	May 08, 2023
Document Information [Line Items]
Document Type	10-Q
Entity Registrant Name	GreenLight Biosciences Holdings, PBC
Amendment Flag	false
Entity Central Index Key	0001822691
Document Quarterly Report	true
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity File Number	001-39894
Entity Tax Identification Number	85-1914700
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	29 Hartwell Avenue
Entity Address, City or Town	Lexington
Entity Address, State or Province	MA
City Area Code	617
Local Phone Number	616-8188
Entity Address, Postal Zip Code	02421
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	GRNA
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		151,681,314
Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each exercisable for one share of Common Stock for $11.50 per share
Trading Symbol	GRNAW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 32,350	$ 68,097
Prepaid expenses and other current assets	5,347	3,214
Total Current Assets	37,697	71,311
Restricted cash	1,411	1,321
Property and equipment, net	40,441	41,365
Operating lease right-of-use assets	32,740	32,766
Other assets	1,400	1,835
TOTAL ASSETS	113,689	148,598
CURRENT LIABILITIES
Accounts payable	1,073	839
Accrued expenses	11,478	13,544
Operating lease liabilities, current portion	4,083	3,358
Long-term debt, current portion	13,782	13,229
Deferred revenue	47	3,866
Other current liabilities	724	724
Total Current Liabilities	31,187	35,560
Warrant liabilities	15	242
Operating lease liabilities, net of current portion	48,702	49,569
Long-term debt, net of current portion	10,858	14,326
Other liabilities	991	839
TOTAL LIABILITIES	91,753	100,536
COMMITMENTS AND CONTINGENCIES (Note 17)
STOCKHOLDERS' EQUITY
Common stock, $0.0001 par value; 500,000,000 shares authorized, 151,681,314 and 151,587,165 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	15	15
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized, no shares issues and outstanding at March 31, 2023 and December 31, 2022, respectively
Additional paid-in capital	471,028	468,685
Accumulated deficit	(449,107)	(420,638)
TOTAL STOCKHOLDERS EQUITY	21,936	48,062
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 113,689	$ 148,598

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) (Unaudited) - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Feb. 02, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000		500,000,000
Common stock, shares issued	151,681,314	151,587,165
Common stock, shares outstanding	151,681,314	151,587,165		122,822,134
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000		10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
REVENUE:
License and collaboration revenue	$ 3,820	$ 0
Grant revenue	0	257
Total revenue	3,820	257
OPERATING EXPENSES:
Research and development	23,168	27,281
General and administrative	8,944	9,755
Total operating expenses	32,112	37,036
LOSS FROM OPERATIONS	(28,292)	(36,779)
OTHER INCOME (EXPENSE):
Interest and other income (expense), net	603	4
Interest expense	(1,007)	(1,073)
Change in fair value of warrant liabilities	227	(359)
Total other income (expense), net	(177)	(1,428)
Net loss	$ (28,469)	$ (38,207)
Net loss per share - basic	$ (0.19)	$ (0.34)
Net loss per share - diluted	$ (0.19)	$ (0.34)
Weighted-average common stock outstanding - basic	151,614,008	113,558,404
Weighted-average common stock outstanding - diluted	151,614,008	113,558,404

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	Convertible Notes - PIPE Investors [Member]	Common Stock	Common Stock Convertible Notes - PIPE Investors [Member]	Additional Paid-in Capital	Additional Paid-in Capital GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	Additional Paid-in Capital Convertible Notes - PIPE Investors [Member]	Accumulated Deficit
Balance at Dec. 31, 2021	$ (29,975)			$ 10		$ 223,584			$ (253,569)
Balance (in Shares) at Dec. 31, 2021				96,575,107
Cashless exercise of Legacy GreenLight preferred stock warrants	460					460
Cashless exercise of Legacy GreenLight preferred stock warrants (in Shares)				490,031
Cashless exercise of Legacy GreenLight common stock warrants	1,183					1,183
Cashless exercise of Legacy GreenLight common stock warrants (in Shares)				170,981
Reclassification of Legacy GreenLight common stock warrants to equity		$ 352					$ 352
Conversion of convertible notes	18,291		$ 35,250	$ 1		18,290		$ 35,250
Conversion of convertible notes (in Shares)				6,719,116	3,525,000
Business Combination transaction, net of transaction costs of $26.7 million	72,989			$ 2		72,987
Business Combination transaction, net of transaction costs of $26.7 million (in Shares)				15,285,374
Vesting of restricted stock awards (in Shares)				1,567
Exercise of common stock options	22					22
Exercise of common stock options (in Shares)				79,055
Stock-based compensation expense	2,187					2,187
Exercise of public warrants	1,209					1,209
Exercise of public warrants (in Shares)				105,120
Other	65					79			(14)
Other (in Shares)				29,154
Net loss	(38,207)								(38,207)
Balance at Mar. 31, 2022	63,826			$ 13		355,603			(291,790)
Balance (in Shares) at Mar. 31, 2022				122,980,505
Balance at Dec. 31, 2022	48,062			$ 15		468,685			(420,638)
Balance (in Shares) at Dec. 31, 2022				151,587,165
Exercise of common stock options	35					35
Exercise of common stock options (in Shares)				94,149
Stock-based compensation expense	2,308					2,308
Net loss	(28,469)								(28,469)
Balance at Mar. 31, 2023	$ 21,936			$ 15		$ 471,028			$ (449,107)
Balance (in Shares) at Mar. 31, 2023				151,681,314

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Parentheticals) (Unaudited) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001
Business combination transaction cost | $	$ 26.7

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (28,469)	$ (38,207)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	2,334	2,096
Gain on disposal of property and equipment		(9)
Stock-based compensation expense	2,308	2,187
Non-cash interest expense	109	335
Change in fair value of warrant liabilities	(227)	359
Change in operating lease right of use asset	1,031	1,631
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,842)	(6,259)
Accounts receivable		(5,000)
Accounts payable	233	(1,952)
Accrued expenses, lease liabilities and other liabilities	(2,718)	(9,435)
Deferred revenue	(3,819)	4,743
Net cash used in operating activities	(31,060)	(49,511)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment		37
Purchases of property and equipment	(1,608)	(287)
Net cash used in investing activities	(1,608)	(250)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from business combination, net of of transaction costs		80,491
Proceeds from stock option exercises	35	22
Principal payments on debt	(2,941)	(815)
Exercise of public warrants		1,209
Principal payments on finance lease obligations	(83)	(160)
Net cash provided by financing activities	(2,989)	102,497
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(35,657)	52,736
Cash, cash equivalents and restricted cash, beginning of period	69,418	31,808
Cash, cash equivalents and restricted cash, end of period	33,761	84,544
SUPPLEMENTAL DISCLOSURE OF CASH-FLOW INFORMATION
Cash paid for interest	744	620
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment included in accrued expenses and accounts payable	$ 396	1,313
Conversion of convertible debt to equity		53,541
Legacy GreenLight cashless warrant exercises		1,643
Warrant liabilities assumed in the Business Combination		1,341
Deferred financing costs in accrued expenses and accounts payable		1,948
PIPE Investors [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debt - PIPE Investors		$ 21,750

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]
Cash and cash equivalents:	$ 32,350	$ 68,097	$ 83,223
Restricted cash	1,411	1,321	1,321
Total cash, cash equivalents and restricted cash	$ 33,761	$ 69,418	$ 84,544	$ 31,808

Nature of Business and Basis of

Nature of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Organization GreenLight Biosciences Holdings, PBC (formerly known as Environmental Impact Acquisition Corp.) (“New GreenLight,” “ENVI” or the “Company”) was incorporated in Delaware on July 2, 2020. The Company has developed technology to create high-performing, natural ribonucleic acid (“RNA”) products to address global sustainability challenges and promote healthier plants, foods, and people. The Company is located and headquartered in Lexington, Massachusetts. The Company has additional lab and office space in Durham, North Carolina, additional lab and office space in Woburn, Massachusetts, additional lab and office space in Medford, Massachusetts, a research station in Spain, and a manufacturing facility in Rochester, New York. The Company’s revenues and expenses are primarily derived from operations in the United States. Since its inception, the Company has devoted substantially all of its efforts to research and development activities, including the development of the Company’s cell-free RNA production process. The Company does not currently generate revenue from sales of any products. On August 9, 2021, ENVI entered into the business combination agreement (“Business Combination Agreement”) with its wholly owned subsidiary, Honey Bee Merger Sub, Inc. (“Merger Sub”) and GreenLight Biosciences, Inc. ("Greenlight"), which was incorporated in Delaware in 2008. Pursuant to the Business Combination Agreement, on February 2, 2022 (the "Closing Date"), Merger Sub merged with and into GreenLight (the “Merger”), with GreenLight surviving the Merger as a wholly owned subsidiary of ENVI (the Merger, together with the other transactions contemplated by the Business Combination Agreement, the “Business Combination”). In connection with the consummation of the Merger on the Closing Date, ENVI changed its name to GreenLight Biosciences Holdings, PBC (“New GreenLight”) and became a public benefit corporation. References to “Legacy GreenLight” refer to GreenLight Biosciences, Inc. prior to the consummation of the Business Combination. Although New GreenLight was the legal acquirer of GreenLight in the Business Combination, GreenLight is deemed to be the accounting acquirer, and the historical financial statements of GreenLight became the basis for the historical financial statements of New GreenLight upon the closing of the Business Combination. New GreenLight, together with its wholly owned subsidiaries, GreenLight Biosciences, Inc., GreenLight Pandemic Response, Inc. (“GLPRI”), GreenLight Security Corporation (“GLSC”), and GreenLight Biosciences España, S.L. ("GLESP") is referred to on a consolidated basis as the “Company”. Upon the closing of the Business Combination, each share of Legacy GreenLight stock was exchanged for shares of Class A common stock in an amount determined by application of the exchange ratio of approximately 0.6656 (the “Exchange Ratio”). In connection with the Business Combination, the Company entered into subscription agreements with subscribers who agreed to purchase an aggregate of 12,425,000 shares of Class A common stock for a purchase price of $ 124.3 million (the “PIPE”), all of which were issued on the effective date. Of the total $ 124.3 million of PIPE proceeds, $ 13.5 million was received in December 2021 and $ 21.8 million was received in January 2022 in the form of convertible notes. Upon the closing of the Business Combination, these convertible notes converted into Class A common stock. In total, the Company received proceeds of $ 136.4 million inclusive of the PIPE and after redemptions which provided the Company with cash of $ 109.7 million, which is net of transaction costs of $ 26.7 million consisting of equity underwriting, legal, and other professional fees, all of which were recorded to additional paid‐in capital as a reduction of proceeds. Further, the Company assumed the outstanding Public Warrants to purchase 10,350,000 shares of the Company’s common stock at $ 11.50 per share and the outstanding Private Placement Warrants to purchase 2,062,500 shares of the Company’s Class A common stock at $ 11.50 per share. The Public and Private Placement Warrants expire five years after the completion of the Business Combination. Both the Private Placement Warrants and Public Warrants are further described in the Business Combination Agreement. Legacy GreenLight was deemed to be the accounting acquirer in the Business Combination. The determination was primarily based on Legacy GreenLight's stockholders having a majority of the voting power in the combined Company, Legacy GreenLight having the ability to appoint a majority of the Board of Directors of the Company, Legacy GreenLight’s existing management team comprising the senior management of the combined Company, Legacy GreenLight comprising the ongoing operations of the combined Company and the combined Company assuming GreenLight’s name. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy GreenLight issuing stock for the net assets of ENVI, accompanied by a recapitalization. The net assets of ENVI are stated at historical cost, with no goodwill or other intangible assets recorded. Futhermore, the historical financial statements of Legacy GreenLight became the historical financial statements of the combined Company upon the consummation of the Business Combination. As a result, the financial statements included in this report reflect (i) the historical operating results of Legacy GreenLight prior to the Business Combination; (ii) the combined results of ENVI and Legacy GreenLight following the close of the Business Combination; (iii) the assets and liabilities of Legacy GreenLight at their historical cost; and (iv) Legacy GreenLight’s equity structure for all periods presented, as affected by the recapitalization presentation after completion of the Business Combination. In accordance with guidance applicable to these circumstances, the equity structure has been restated in all comparable periods up to February 2, 2022, to reflect the number of shares of the Company’s common stock, $ 0.0001 par value per share, issued to Legacy GreenLight’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy GreenLight’s outstanding convertible preferred stock and Legacy GreenLight's common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of 0.6656 established in the Business Combination. Legacy GreenLight’s convertible preferred stock previously classified as temporary equity was retroactively adjusted, converted into common stock and reclassified to permanent equity as a result of the reverse recapitalization. See Note 3 - Business Combination for further details of the Business Combination. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and applicable rules and regulations of the U.S. Securities and Exchange Commission ("SEC") regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany transactions and balances have been eliminated in consolidation. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed consolidated or omitted pursuant to such rules and regulations. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods presented. The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for any subsequent quarter, the fiscal year ending December 31, 2023, or any other period. Liquidity and Going Concern Since its inception, the Company has devoted substantially all of its resources to building its platform and advancing development of its portfolio of programs, establishing, and protecting its intellectual property, conducting research and development activities, organizing, and staffing the Company, business planning, raising capital and providing general and administrative support for these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive field trials, preclinical and clinical trials, and regulatory approvals prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. As presented in the financial statements, the Company has incurred substantial losses since inception and incurred net losses of approximately $ 28.5 million and $ 38.2 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the Company had an accumulated deficit of approximately $ 449.1 million and cash and cash equivalents of approximately $ 32.4 million. Cash used in operating activities totaled approximately $ 31.1 million and $ 49.5 million for three months ended March 31, 2023 and 2022, respectively. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future. As of the issuance date of the Company's unaudited interim condensed consolidated financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022, the Company estimates that its existing cash and cash equivalents of approximately $ 32.4 million as of March 31, 2023 will last through the second quarter of 2023 but will not be sufficient to fund its operations for twelve months from the date these interim financial statements are issued. The Company is evaluating a range of opportunities to extend its cash runway, including management of program spending, platform licensing collaborations and potential financing activity. The Company will not generate any revenue from product sales unless and until it successfully completes development and obtains regulatory approval for one or more of its product candidates. If the Company obtains regulatory approval for any of its product candidates, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution. As a result, the Company will need substantial additional funding to support its operating activities as it advances its product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings, debt financings, and license and development agreements in connection with any future collaborations. Adequate funding may not be available to the Company on acceptable terms, or at all. As described below in Item 2 of this Form 10-Q, the Company received a non-binding indication of interest from Fall Line Endurance Fund, L.P. to acquire all of the outstanding capital stock of the Company. The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction. GreenLight’s Board of Directors through a Special Committee thereof is carefully evaluating Fall Line’s indication of interest within the context of the ongoing review of various alternatives and in consultation with its retained financial and legal advisors. No assurance can be given that a definitive transaction with respect to Fall Line’s indication of interest or any other potential transaction will eventually be consummated. If the Company is unable to obtain funding or if the funding it does obtain is insufficient to support its current operational plans, the Company will be forced to delay, reduce, or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. In the event the Company is unable to secure additional outside capital to fund our obligations when they become due over the next 12 months, the Company will be required to seek other strategic alternatives, which may include, among others, scaling back or discontinuing certain or all operations to reduce costs, closure of operations, sale of certain of our assets, a sale of the entire company to strategic or financial investors, and/or seeking protection under the U.S. bankruptcy laws. Although management continues to pursue plans to raise additional funding, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. Based on its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future, and need to raise additional capital to finance its future operations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the issuance date of these condensed consolidated financial statements. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Summary of Significant Accounting Policies [Line Items]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s significant accounting policies are described in Note 2 to the Company’s consolidated financial statements included in the 2022 Form 10-K. There have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2023. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development costs, the fair values of common stock (as defined below), useful lives assigned to property and equipment, and the fair value of warrant liabilities. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Concentrations of Credit Risk The Company has no significant off-balance sheet credit risk. Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, restricted cash and accounts receivable. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Concentration of credit risk with respect to accounts receivable is limited to customers with whom the Company has entered into collaboration agreements. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver and SVB was subsequently transferred into a new entity, Silicon Valley Bridge Bank, N.A (“SVB Bridge Bank”). On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors’ insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its full deposits with SVB Bridge Bank. On March 27, 2023, First Citizens Bank & Trust Company assumed all of SVB's deposits and loans. In light of the foregoing, the Company does not believe that it has exposure to loss as a result of SVB's receivership. As of March 31, 2023, the Company held $ 18.6 million in SVB and has not experienced any losses on its deposits of cash, cash equivalents and restricted cash. Leases The Company determines if an arrangement is a lease or contains a lease at inception. Our lease agreements are generally for office and laboratory facilities under operating leases and certain equipment under financing leases, and the determination of whether such agreements contain leases generally does not require significant estimates or judgments. Our leases may also contain non-lease components such as payments of maintenance, utilities, and taxes, which we have elected to account for separately, as these amounts are readily determinable. For leases with terms greater than 12 months, the Company records a related right-of-use (“ROU”) asset and lease liability at the present value of lease payments over the term, discounted using our incremental borrowing rate (“IBR”) over the lease term (or, if readily determinable, the rate implicit in the lease). Many leases include fixed rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when appropriate. The right-of-use asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred and excludes lease incentives. The lease term used to measure right-of-use lease assets and lease liabilities may include renewal options which are deemed reasonably certain to be exercised. Operating lease costs are recognized on a straight-line basis over the lease term. Variable lease payments are expensed as incurred. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. This new standard is effective for the Company in the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company adopted ASU 2016-03 as of January 1, 2023 , with no impact on our condensed consolidated financial statements or the related disclosures.

Business Combination

Business Combination	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
BUSINESS COMBINATION	3. BUSINESS COMBINATION On February 2, 2022, Legacy GreenLight consummated a Business Combination with ENVI. The Business Combination, and the PIPE financing which was entered into as of the same date, are further described in Note 1 - Nature of Business and Basis of Presentation . Upon the closing of the Business Combination, the Company's certificate of incorporation was amended and restated to, among other things, increase the total number of authorized shares of all classes of capital stock to 510,000,000 shares, of which 500,000,000 were designated as common stock and 10,000,000 were designated as preferred stock, both having a par value of $ 0.0001 per share. Upon the closing of the Business Combination, holders of Legacy GreenLight common stock and preferred stock received shares of common stock in an amount determined by application of the Exchange Ratio. Legacy GreenLight additionally converted all of its convertible notes, including both the GLPRI issued convertible notes and the PIPE prepayment notes, to shares of common stock. For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy GreenLight. The following table reconciles the elements of the Business Combination to the Condensed Consolidated Statements of Cash Flows and the Condensed Consolidated Statements of Stockholders’ Defic it: BUSINESS COMBINATION Cash - ENVI trust and cash (net of redemptions) $ 12,123 Cash - PIPE Investors, including proceeds from conversion of Convertible notes - PIPE Investors 124,250 Gross proceeds 136,373 Less: total transaction costs ( 26,660 ) Less: cash proceeds from Convertible notes - PIPE Investors ( 35,250 ) Add: transaction costs paid in 2021 4,080 Cash proceeds from Business Combination received in 2022 78,543 Less: transaction costs paid in 2021 ( 4,080 ) Less: warrant liabilities assumed ( 1,341 ) Less: net liabilities assumed in the Business Combination ( 133 ) Reverse merger, net of transactions costs $ 72,989 The number of shares of common stock outstanding immediately following the consummation of the Business Combination was as follows: Number of Shares Common stock, outstanding prior to the Business Combination 20,700,000 Less: Redemption of ENVI shares ( 19,489,626 ) ENVI Public Shares 1,210,374 ENVI Sponsor Shares 5,175,000 Shares issued in PIPE financing 12,425,000 Business combination and PIPE financing shares 18,810,374 Legacy GreenLight shares (1) 104,011,760 Total shares of common stock immediately after Business Combination 122,822,134 (1) - The number of Legacy GreenLight shares was determined from the shares of Legacy GreenLight outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio. All fractional shares were rounded down. Public Warrants The Company concluded that following the close of the transaction the Public Warrants met the criteria for equity classification. As of the Closing Date, the 10,350,000 shares of Public Warrants were classified as equity as described within Note 11 - Warrants and recognized in additional paid-in capital. Private Placement Warrants As of the Closing Date, the total value of the liability associated with the Private Placement Warrants was $ 1.3 million. The Company concluded that the 2,062,500 shares of Private Warrants met the definition of a liability as described in Note 11 - Warrants and have been classified as such on the balance sheet. At March 31, 2023 , the fair value of the warrant liability was an immaterial amount.

License Agreement

License Agreement	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
License Agreements	4. LICENSE AGREEMENT Acuitas License Agreement In August 2020, the Company entered into a Development and Option Agreement (the “Development and Option Agreement”) with Acuitas Therapeutics, Inc. (“Acuitas”). Under the terms of the Development and Option Agreement, the parties agreed to a program for the joint development of certain products combining the Company’s mRNA constructs with Acuitas’ liquid nanoparticle technology (“Acuitas LNP Technology”). Upon entering the Development and Option Agreement, the Company incurred a $ 0.8 million technology access fee. Under the Development and Option Agreement, the Company may reserve up to three specified targets (“Reserved Targets”) for development of therapeutic products related to such targets, using the Acuitas LNP Technology. In order to reserve a Reserved Target, the Company must provide a target reservation notice to Acuitas and must pay a target reservation and maintenance fee of $ 0.1 million per target per contract year. For each Reserved Target, the Company may also reserve up to three additional vaccine or antibody targets meant to be included within the same product as the Reserved Target (“Additional Targets”), which incur additional target reservation fees per contract year. Under the Development and Option Agreement, the Company is required to maintain at least one Reserved Target. Under the Development and Option Agreement, the Company has the right to exercise a license option to develop and commercialize one or more therapeutic products relating to each Reserved Target. In the event that the Company exercises the options, the Company will pay $ 1.5 million for the first non-exclusive license, approximately $ 1.8 million for the second non-exclusive license and approximately $ 2.8 million for the third non-exclusive license. Under the terms of the Development and Option Agreement, the Company is also responsible for the full-time employee fun ding obligations and reimbursements to Acuitas for certain development and material costs incurred by them, which totaled approximately $ 0.5 million i n 2021. The Company did not incur any full-time employee funding obligations reimbursable to Acuitas for the three months ended March 31, 2023. In January 2021, the Company exercised the first option under the Development and Option Agreement and entered into a non-exclusive license agreement with Acuitas (the “Acuitas License Agreement”), under which the Company was granted a non-exclusive, worldwide, sublicensable license under the Acuitas LNP Technology to research, develop, manufacture, and commercially exploit vaccine products consisting of certain of the Company’s mRNA constructs and Acuitas' LNP technology. In connection with the option exercise, the Company paid Acuitas an option exercise fee of $ 1.5 million. Under the Acuitas License Agreement, the Company is required to pay Acuitas an annual license maintenance fee of $ 1.0 million for the first and second targets and $ 0.8 million for the third target until the Company achieves a particular development milestone. Acuitas is entitled to receive potential clinical and regulatory milestone payments in the low double-digit millions for this exercised option. With respect to the sale of each licensed product, the Company is also obligated to pay Acuitas percentage royalties in the low single digits on net sales of the licensed products by the Company and its affiliates and sublicensees in a given country until the last to occur, in such country, of (i) the expiration or abandonment of all licensed patent rights covering the licensed product, (ii) expiration of any regulatory exclusivity for the licensed product, or (iii) ten years from the first commercial sale of the licensed product. The option exercise fee under the Development and Option Agreement was recorded as research and development expense upon the Company’s exercise of the first option. Additionally, the technology access fees, target reservation and maintenance fees, expenses associated with the full-time employee funding obligations and reimbursements for development and material costs incurred by Acuitas are recorded as research and development expense when incurred. The annual maintenance fee will be recorded as an expense on an annual basis based on the stated amount for the applicable year. Upon determination that a milestone payment is probable to occur, the amount of the milestone payment will be recorded as research and development expense. As the triggering of these milestone payments was not considered probable as of March 31, 2023 and December 31, 2022 , no expense has been recorded during these periods. The royalty payment is contingent upon sales of licensed products un der the Acuitas License Agreement. As such, when such expenses are considered probable and estimable at the commencement of sales, the Company will accrue royalty expense for the amount the Company is obligated to pay. The Company recorded an aggregate of $ 0.4 million and $ 0.3 million of research and development expenses, consisting of the technology access fees, option exercise fee and technology maintenance fees, for the three months ended March 31, 2023 and 2022, respectively.

License and Collaboration Agree

License and Collaboration Agreements	3 Months Ended
	Mar. 31, 2023
License and Collaboration Agreements [Abstract]
License and Collaboration Agreements	5. LICENSE AND COLLABORATION AGREEMENT Serum License Agreement In March 2022 , the Company entered into a License Agreement (the “Agreement”) with Serum Institute of India Private Limited (“SIIPL”), pursuant to which the Company granted SIIPL an exclusive, sub-licensable, royalty-bearing license to use the Company’s proprietary technology platform to develop, manufacture and commercialize up to three mRNA products in all territories other than the United States, the 27 member states of the European Union, the United Kingdom, Australia, Japan, New Zealand, Canada, South Korea, China, Hong Kong, Macau, and Taiwan (the “SIIPL Territory”). The first licensed product target will be a shingles product target, and SIIPL has an option to select the additional two licensed product targets through the end of 2024. Under the terms of the Agreement with SIIPL, the Company will provide research services related to the shingles product target to develop a “proof of concept” and will provide manufacturing technology transfer services. In addition, GreenLight retains the option to purchase research and clinical trial data, developed by SIIPL, for 50 % of the cost of the research studies and clinical trials for use in the Company’s own development. SIIPL is responsible for the development, formulation, filling and finishing, registration and commercialization of the products in the SIIPL Territory, subject to oversight from a joint steering committee composed of representatives of the Company and SIIPL. SIIPL will use commercially reasonable efforts to develop and obtain regulatory approval for the products in the countries in the SIIPL Territory. The License Agreement includes terms customary in the industry for provisions related to sublicensing, intellectual property, and termination, and customary representations and warranties of GreenLight and SIIPL, along with certain customary covenants, including confidentiality, limitation of liability and indemnity provisions. Pursuant to the License Agreement, SIIPL will pay the Company an upfront license fee of $ 5.0 million, as well as payments upon additional target selection and reservation of exclusivity. The Company may receive up to a total of an additional $ 17.0 million in development, regulatory and commercial (net sales) based milestone payments across all three product targets, as well as manufacturing technology transfer payments up to $ 10.0 million. SIIPL shall pay royalty payments in the mid-double digits, based on the net sales of products resulting from the licensed technology for the term of the License Agreement. The License Agreement shall terminate on a product-by-product and country-by-country basis on the later of the expiration of the patent rights owned by the Company or the tenth anniversary of the first commercial sale of the applicable product(s) in the applicable country. The Company has determined that the Agreement falls within the scope of ASC 606, Revenue Recognition, ("ASC 606") as it includes a customer-vendor relationship as defined by ASC 606 and thus represents a contract with a customer. The Company has determined that the license of IP granted is not distinct from the research services, which includes manufacturing technology transfer services, and thus should be combined. The Agreement contains a single performance obligation for the combined License of IP and research services. Revenue from the contract is being recognized over time, using an input-method based on labor costs as a percentage of total expected labor costs. The Company has determined that variable consideration from the development and regulatory payments of up to $ 17.0 million, as well as the remaining $ 5.0 million of the manufacturing technology transfer payment, in the Agreement should be fully constrained as of March 31, 2023, and commercial milestones and royalties will be recognized in the period the underlying sales occur. For the three months ended March 31, 2023 , the Company has recorded revenue of $ 3.8 million from the Agreement and the remaining amount of billed and unconstrained consideration is recorded as deferred revenue. There was no revenue recorded under the Agreement for the three months ended March 31, 2022. Based on current estimated timelines, the Company expects to recognize the deferred revenue over approximately 12 months and is classified as current in the condensed consolidated balance sheet as of March 31, 2023 .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
FAIR VALUE MEASUREMENTS	6. FAIR VALUE MEASUREMENTS The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2023 and December 31, 2022: DESCRIPTION MARCH 31, 2023 QUOTED PRICES SIGNIFICANT SIGNIFICANT ($ in thousands) Asset Money market funds $ 32,350 $ 32,350 $ — $ — Total assets measured at fair value $ 32,350 $ 32,350 $ — $ — Liability Warrant liabilities $ 15 $ — $ — $ 15 Total liabilities measured at fair value $ 15 $ — $ — $ 15 DESCRIPTION DECEMBER 31, QUOTED PRICES SIGNIFICANT SIGNIFICANT ($ in thousands) Asset Money market funds $ 68,097 $ 68,097 $ — $ — Total assets measured at fair value $ 68,097 $ 68,097 $ — $ — Liability Warrant liabilities $ 242 $ — $ — $ 242 Total liabilities measured at fair value $ 242 $ — $ — $ 242 Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There have been no transfers between fair value levels during the three months ended March 31, 2023 and 2022, respectively. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the common stock warrant liabilities was determined using the Black-Scholes option-pricing model with the assumptions as disclosed in Note 11 - Warrants . These assumptions include significant judgments including the fair value of the underlying common stock and volatility. An increase or decrease in the estimated fair value or changes in volatility will result in increases or decreases in the fair value of the warrant liabilities and such changes could be material. The carrying value of each of the Horizon term loan and the SVB term loan as of March 31, 2023, and December 31, 2022 approximates their fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics. The carrying value of the equipment financing does not approximate its fair value because the instrument bears interest at a rate that is not compared to those available to the Company for a similar instrument as of March 31, 2023. The Company estimated the fair value of the equipment financing using a discounted cash flow analysis and prevailing market terms as of March 31, 2023. The carrying value and fair value of the equipment financing was $ 5.0 million and $ 4.8 million as of March 31, 2023. See Note 10 - Debt for further detail of all outstanding debt as of March 31, 2023. The following table presents a roll-forward of the aggregate fair values of the Company’s liabilities for which fair value is determined by Level 3 inputs for the three months ended March 31, 2023 (in thousands): WARRANT LIABILITY Balance—December 31, 2022 $ 242 Change in fair value of warrants ( 227 ) Balance—March 31, 2023 $ 15

Grant Revenue

Grant Revenue	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Grant Revenue [Line Items]
Grant Revenue	7. GRANT REVENUE In July 2020, the Company was approved to receive a grant from the Bill & Melinda Gates Foundation in the amount of approximately $ 3.3 million. As of December 31, 2021, the Company had received the entire grant award, of which approximately $ 2.4 million was received during the year ended December 31, 2020, and the remaining approximately $ 0.9 million was received during the year ended December 31, 2021. The grant funds are to be used for the sole purpose of research for in vivo gene therapy for sickle cell disease and to expl ore new, low-cost capabilities for the in vivo functional cure of sickle cell and or durable suppression of HIV in developing countries. The Company incurred research and development costs of approximately $ 0.3 million associated with this grant for the three months ended March 31, 2022. The Company has recognized revenue of approximately $ 0.3 million for the three months ended March 31, 2022. The Company did no t incur any research and development costs and has not recognized any revenue for the three months ended March 31, 2023 associated with this grant. As of March 31, 2023, we ceased any ongoing research work under such grant, completed close-out activities and are in the process of returning any remaining unused funds to the Gates Foundation. The Company has recorded $ 0.8 million in other current liabilities on the condensed consolidated balance sheet as of March 31, 2023 and December 31, 2022, respectively, as we are required to return all unspent funds to the Gates Foundation.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Net	8. PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following as of March 31, 2023 and December 31, 2022: MARCH 31, DECEMBER 31, ($ in thousands) Leasehold improvements $ 25,196 $ 25,175 Laboratory equipment 25,162 24,373 Manufacturing and farm equipment 1,495 1,450 Computer hardware and software 1,394 1,338 Furniture and fixtures 702 702 Construction in progress 1,847 1,348 Total 55,796 54,386 Less: Accumulated depreciation and amortization ( 15,355 ) ( 13,021 ) Property and equipment, net $ 40,441 $ 41,365 As of March 31, 2023 and December 31, 2022 , property and equipment, net included capital lease assets of approximately $ 2.6 million and $ 2.6 million, respectively, with accumulated amortization of approximately $ 2.1 million and $ 2.0 million, respectively. Depreciation and amortization expense for the three months ended March 31, 2023 and 2022 was approximately $ 2.3 million and $ 2.1 million, respectively.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Accrued Liabilities, Current [Line Items]
Accrued Expenses	9. ACCRUED EXPENSES Accrued expenses as of March 31, 2023 and December 31, 2022 consisted of the following: MARCH 31, DECEMBER 31, ($ in thousands) Accrued employee compensation and benefits $ 6,304 $ 5,998 Accrued research and development 1,448 3,041 Accrued professional fees 1,281 1,152 Accrued other 2,445 3,353 Total accrued expenses $ 11,478 $ 13,544

Debt

Debt	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Debt	10. DEBT A summary of the outstanding debt as of March 31, 2023 is as follows (in thousands): AS OF MARCH 31, 2023 DESCRIPTION ISSUANCE DATE(S) MATURITY DATE(S) INTEREST RATE PRINCIPAL BALANCE OUTSTANDING UNAMORTIZED DEBT DISCOUNT DEBT BALANCE Trinity Equipment Financing March 2021 - August 2021 March 2024 - August 2024 9.48 % - 9.73 % $ 4,963 $ ( 120 ) $ 4,843 Term Loan – Silicon Valley Bank September 2021 September 2024 8.25 % 6,000 ( 74 ) 5,926 Term Loan – Horizon December 2021 July 2025 13.75 % 14,000 ( 285 ) 13,715 Finance Lease 156 — 156 Total Debt 25,119 ( 479 ) 24,640 Less: current portion ( 13,782 ) Total long-term $ 10,858 A summary of the outstanding debt as of December 31, 2022 is as follows (in thousands): AS OF DECEMBER 31, 2022 DESCRIPTION ISSUANCE DATE(S) MATURITY DATE(S) STATED INTEREST RATE PRINCIPAL BALANCE OUTSTANDING UNAMORTIZED DEBT DISCOUNT DEBT BALANCE Trinity Equipment Financing March 2021 - August 2021 March 2024 - August 2024 9.48 % - 9.73 % $ 5,905 $ ( 146 ) $ 5,759 Term Loan - Silicon Valley Bank September 2021 September 2024 7.75 % 7,000 ( 98 ) 6,902 Term Loan - Horizon December 2021 July 2025 13.25 % 15,000 ( 343 ) 14,657 Finance Lease 237 — 237 Total Debt 28,142 ( 587 ) 27,555 Less: current portion ( 13,229 ) Total long-term $ 14,326 Convertible Instruments -PIPE Investors In December 2021, certain new and existing investors in GreenLight (the “Prepaying PIPE Investors”) agreed to purchase from GreenLight convertible instruments with an aggregate principal amount of approximately $ 35.3 million (the “PIPE Instruments”). The Company received $ 13.5 million in December 2021 and $ 21.8 million in January 2022. In conjunction with entering into the PIPE Instruments, each PIPE Investor entered into a side letter agreement (the “Side Letter”) with GreenLight, which required the PIPE Investor to tender its PIPE Instrument as a corresponding payment for all or a portion of such PIPE Investor’s purchase of shares upon the closing of a business combination. In February 2022, in accordance with the Business Combination, $ 35.3 million of the PIPE Instruments were surrendered, cancelled, and converted into shares of common stock. The Company determined that the cancellation and conversion of the PIPE Instruments represented an extinguishment for accounting purposes. Term Loan – Horizon In December 2021, the Company entered into a loan and security agreement with Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP (together, “Horizon”), which provided for a term loan facility in an aggregate principal amount of up to $ 25.0 million, $ 15.0 million of which was borrowed at the closing and the remainder of which may be borrowed following the achievement of certain milestones, but not after June 30, 2022. As of June 30, 2022, the Company had not borrowed, and could no longer borrow the remainder of the term loan. Accrued interest is payable monthly. The principal of each term loan must be repaid in equal monthly installments beginning February 1, 2023 , with a scheduled final maturity date of July 1, 2025 . The Company may prepay the term loans in full, but not in part, without premium or penalty, other than a premium equal to (i) 3 % of the principal amount of any prepayment made within 12 months after the applicable funding date, (ii) 2 % of the principal amount of any prepayment made between 12 and 24 months after the applicable funding date and (iii) 1 % of the principal amount of any prepayment made more than 24 months after the applicable funding date. On the earlier of the scheduled final maturity date and the prepayment in full of the term loans, the Company must pay a final payment fee equal to 3.0 % of the original principal amount of the funded term loans. The final payment is being accreted to interest expense over the term of the loan using the effective interest method and is being recorded in other liabilities on the Company's condensed consolidated balance sheets. The debt was recorded based on proceeds received net of related debt issuance costs of approximately $ 0.6 million, which is being amortized over the term of this financing agreement. The debt issuance costs include the fair value of approximately $ 0.4 million for the warrants t he Company is committed to issue in conjunction with this financing. The warrants were issued on January 19, 2022. See Note 11 - Warrants for further discussion of the warrants. Term Loan – Silicon Valley Bank In September 2021, the Company entered into a loan and security agreement with Silicon Valley Bank (“SVB”), which provided for a term loan facility in an aggregate principal amount of up to $ 15.0 million, $ 10.0 million of which was borrowed at the closing and the remainder of which may be borrowed following the achievement of certain milestones, but not after March 31, 2022. As of March 31, 2022, the Company had not borrowed, and could no longer borrow the remainder of the term loan. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver and SVB was subsequently transferred into a new entity, Silicon Valley Bridge Bank, N.A (“SVB Bridge Bank”). The loan and security agreement with SVB contains customary affirmative and negative covenants and customary events of default; it does not contain a financial covenant. The loan and security agreement with SVB also includes the obligation for the Company to maintain cash in accounts with SVB in amounts sufficient to repay all loan obligations, which if not met constitutes an event of default under the agreement. Accrued interest is payable monthly. The principal of each term loan must be repaid in equal monthly installments beginning April 1, 2022 , with a scheduled final maturity date of September 1, 2024 . On the earlier of the scheduled final maturity date and the prepayment in full of the term loans, the Company must pay a final payment fee equal to 4.0 % of the original principal amount of the term loans. The final payment is being accreted to interest expense over the term of the loan using the effective interest method. GreenLight may prepay the term loans in increments of $ 5.0 million and without premium or penalty, other than a premium equal to (i) with respect to any prepayment made on or before September 22, 2022, 3 % of the principal so prepaid, (ii) with respect to any prepayment made after September 22, 2022 and on or before September 22, 2023, 2 % of the principal so prepaid and (iii) with respect to any prepayment made after September 22, 2023 and on or before September 1, 2024, 1 % of the principal so prepaid. GreenLight granted a first-priority, perfected security interest in substantially all of its present and future personal property and assets, excluding intellectual property, to secure its obligations to SVB. The debt was recorded based on proceeds received net of related debt issuance costs of approximately $ 0.3 million. The debt issuance costs include the fair value of approximately $ 0.2 million for the 34,427 warrants to purchase shares of common stock the Company previously issued in conjunction with this financing. No additional common warrants were issued in conjunction with this financing. Total debt issuance costs of approximately $ 0.4 million is being amortized over the term of this financing agreement. Equipment Financing On March 29, 2021, the Company entered into a master equipment financing agreement with Trinity Capital (Trinity) authorizing equipment financing in the aggregate of approximately $ 11.3 million with advances to be made as follows: (1) up to $ 5.0 million at execution of the agreement and (2) the remaining balance to be drawn at the Company’s option but no later than September 1, 2021. The monthly payment factors are determined by Trinity based on the Prime Rate reported in The Wall Street Journal on the first day of the month in which a financing schedule is executed, which as of the effective date of the equipment financing agreement was 3.25 %. As of March 31, 2023 , the Company had drawn the entire $ 11.3 million on multiple advances, which is repayable over a 36 -month period that commenced on the advance date. The historical cost of the assets subject to a lien under this financing arrangement is approximately $ 14.7 million. The debt was recorded based on proceeds received net of related debt issuance costs of approximately $ 0.4 million, which are being amortized over the term of this financing agreement. The debt issuance costs include the fair value of approximately $ 0.1 million for the 146,325 warrants to purchase shares of common stock the Company issued in conjunction with this financing. Convertible Notes In connection with the Merger (See Note 3 - Business Combination ), $ 16.8 million of the Company’s outstanding convertible notes, which were issued in 2020, and accrued interest of $ 1.6 million converted into 10.1 million shares of Series D Preferred Stock. Concurrently with the business combination, the Series D Preferred Stock was exchanged for shares of common stock of New GreenLight in February of 2022. Loan Interest Expense and Amortization Interest expense for the three months ended March 31, 2023 and 2022 consisted of the following: THREE MONTHS ENDED MARCH 31, 2023 2022 ($ in thousands) Interest paid or accrued $ 898 $ 804 Non-cash amortization of debt discount and deferred financing cost 109 224 Total $ 1,007 $ 1,028 Scheduled future principal payments on total outstanding debt, as of March 31, 2023 are as follows (in thousands): MARCH 31, 2023 Remainder of 2023 $ 10,591 2024 11,028 2025 3,500 Total $ 25,119

Warrants

Warrants	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
WARRANTS	11. WARRANTS Common Stock Warrants classified as Liabilities Private Placement Warrants The Private Placement Warrants may not be redeemed by the Company so long as the Private Placement Warrants are held by the initial purchasers, or such purchasers’ permitted transferees. The Private Placement Warrants have terms and provisions identical to those of the Public Warrants which are discussed below, including as to exercise price, exercisability, and exercise period, except if the Private Placement Warrants are held by someone other than the initial purchasers’ permitted transferees, then the Private Placement Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. On the Closing Date and as of March 31, 2023 , there were 2,062,500 Private Warrants issued and outstanding. These warrants are recognized as liabilities on the condensed consolidated balance sheets and were measured at their inception date fair value and subsequently remeasured at each reporting period with changes recorded as a component of other income (expense) in the Company’s condensed consolidated statements of operations. The fair value of the Private Placement Warrants upon initial recognition, as of December 31, 2022 and as of March 31, 2023 was estimated to be approximately $ 1.3 million, $ 0.2 million and $ 15 thousand, respectively, and was measured using a Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AS OF MARCH 31, 2023 AS OF DECEMBER 31, 2022 INITIAL RECOGNITION Fair value of common stock $ 0.43 $ 1.18 $ 8.82 Risk free interest rate 3.70 % 4.05 % 1.59 % Volatility 69.0 % 69.0 % 15.9 % Expected term (in years) 3.75 4.17 5.00 Common Stock Warrants classified as Equity Horizon Debt Warrants In connection with the Loan Agreement the Company entered into with Horizon in December 2021, the Company issued warrants to Horizon to purchase 85,552 shares of the Company’s common stock at an exercise price per share of $ 5.26 for the $ 15.0 million drawn commitment. Upon issuance of these warrants in January 2022, the Company reassessed the classification of the warrants and noted that there was no variability in the number of shares or the exercise price of the warrants. The Company determined that the warrants met the requirements for equity classification and the fair value of $ 0.4 million was reclassified to equity as of March 31, 2022. The warrants' fair value upon issuance was estimated to be approximately $ 0.4 million, and was measured using a Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AT ISSUANCE (AS OF JANUARY 19, 2022) Fair value of common stock $ 5.89 Risk free interest rate 1.50 % Expected volatility 59.60 % Expected term (in years) 10.00 In connection with Loan Agreement the Company entered into with Horizon which provided for a term loan facility in an aggregate principal amount of up to $ 25.0 million, of which $ 15.0 million was borrowed at the closing (See Note 10 - Debt ), the Company issued warrants for both the $ 15.0 million loan drawn at the closing and the remaining $ 10.0 million available commitment which had different terms and conditions. In conjunction with the $ 10.0 million available commitment, the Company made available to Horizon a warrant to purchase up 57,034 shares, of which 28,517 shares of the Company’s common stock were issued at an exercise price per share of $ 5.26 . These warrants were recognized as liabilities and were measured at their inception date fair value and subsequently remeasured at each reporting period with changes recorded as a component of other income in the Company’s condensed consolidated statements of operations. The warrant issued for the $ 10.0 million available commitment is summarized below as a liability-classified Common Stock Warrant. Warrant Class Shares Inception Date Fair Value (in thousands) Issuance Date Exercise Price Expiration Date Common stock warrant 28,517 $ 249 January 19, 2022 $ 5.26 The earlier of March 29, 2031 or the date of a qualifying acquisition The warrant’s fair value upon issuance and as of June 30, 2022 was estimated to be approximately $ 0.2 million and $ 35 thousand, respectively, and was measured using a probability weighted Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AT ISSUANCE (AS OF JANUARY 19, 2022) AS OF Fair value of common stock $ 5.89 $ 2.21 Risk free interest rate 1.50 % 2.39 % Expected volatility 59.60 % 59.60 % Expected term (in years) 10.50 10.00 At June 30, 2022, the Warrants were determined to have met the requirements for equity classification and the fair value of $ 35 thousand was reclassified to equity. Public Warrants Each Public Warrant entitles the holder to the right to purchase one share of common stock at an exercise price of $ 11.50 per share. No fractional shares will be issued upon exercise of the Public Warrants. The Company may elect to redeem the Public Warrants subject to certain conditions, in whole and not in part, at a price of $ 0.01 per Public Warrant if (i) 30 days’ prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company’s common stock equals or exceeds $ 18.00 per share (as adjusted for stock splits, stock divide nds, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis. On the Closing Date, there were 10,350,000 Public Warrants issued and outstanding. In March 2022, 105,120 of the Public Warrants were exercised into shares of the Company's common stock for a total exercise price of $ 1.2 million in cash. The following table presents a summary of the Company’s warrants activity from December 31, 2022 to March 31, 2023: COMMON STOCK WARRANTS Warrants Outstanding, December 31, 2022 12,383,304 Issued — Exercised — Warrants Outstanding, March 31, 2023 12,383,304

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	12. STOCKHOLDERS' EQUITY Authorized share s The Company was authorized to iss ue 500,000,000 shares of $ 0.0001 par value common stock and 10,000,000 shares of $ 0.0001 par value preferred stock as of March 31, 2023 and December 31, 2022, respectively. As of March 31, 2023 and December 31, 2022, the total number of shares of common stock issued and outstanding was 151,681,314 and 151,587,165 , respectively. As of each March 31, 2023 and December 31, 2022, there were 12,383,304 warrants to purchase the Company’s common stock outstanding. As of March 31, 2023 and December 31, 2022, there were no shares of preferred stock issued or outstanding. Legacy Greenlight Redeemable Convertible Preferred Stock In connection with the Business Combination, Legacy Redeemable Convertible Preferred Stock previously classified as temporary equity was retroactively adjusted, converted into common stock at an exchange ratio of approximately 0.6656 , and reclassified to permanent equity as a result of the reverse recapitalization. As of March 31, 2023 and December 31, 2 0 22, there was no Legacy Redeemable Convertible Preferred Stock authorized, issued or outstanding, respectively.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	13. STOCK-BASED COMPENSATION 2022 Stock Incentive Plan On February 1, 2022, stockholders approved the New GreenLight 2022 Equity and Incentive Plan, or the “New GreenLight Equity Plan”, or “Equity Plan”, replacing the GreenLight 2012 Equity Plan (the “2012 Plan”), pursuant to which the Company’s Board of Directors may grant stock options, both incentive stock options and nonstatutory stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, dividend equivalent rights, or cash awards to employees, directors and consultants. In connection with the adoption of the Equity Plan, no further option grants are permitted under the 2012 Plan and any expirations, cancellations, or terminations under the 2012 Plan are available for issuance under the Equity Plan. There are 31,750,000 registered shares of common stock reserved for issuance under the Equity Plan. On January 1, 2023, the number of shares reserved and available for issuance under the Equity Plan increased by 6,063,486 shares of common stock pursuant to a provision in the Equity Plan that provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2023, by 4 % of the number of shares of common stock issued and outstanding on the immediately preceding December 31 or such lesser number as determined by the compensation committee of the board of directors. As of March 31, 2023, 14,494,674 shares remain available for future grants under the Equity Plan. The Plan is administered by the Company’s Board of Directors (the “Board”). The exercise prices, vesting and other restrictions are determined at the discretion of the Board, except that the exercise price per share of incentive stock options may not be less than 100 % of the fair market value of the common stock on the date of grant. Stock options awarded under the Plan expire ten years after the grant date unless the Board sets a shorter term. Vesting periods for awards under the plans are determined at the discretion of the Board. Incentive stock options granted to employees and non-statutory options and restricted stock awards granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over four or five years . The fair value of stock option awards is estimated on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: THREE MONTHS ENDED MARCH 31, 2023 2022 Fair value of underlying common stock $ 0.56 $ 9.15 Weighted average risk-free interest rate 3.89 % 2.56 % Expected term (in years) 6.07 6.00 Expected volatility 56.97 % 56.28 % Expected dividend yield 0.00 % 0.00 % The following table summarizes the activity of the Company’s stock options under the Plan for the three months ended March 31, 2023: AVERAGE AGGREGATE WEIGHTED- REMAINING INTRINSIC AVERAGE CONTRACTUAL VALUE SHARES EXERCISE PRICE TERM (in years) (in thousands) Outstanding at December 31, 2022 23,051,188 $ 2.35 7.8 $ 7,192 Granted 229,500 0.97 — — Exercised ( 94,149 ) 0.37 — — Cancelled or forfeited ( 755,414 ) 3.11 — — Outstanding at March 31, 2023 22,431,125 2.25 7.6 355 Vested and expected to vest at March 31, 2023 22,431,125 2.25 7.6 355 Exercisable at March 31, 2023 11,015,527 $ 1.11 6.3 $ 333 The weighted-average grant date fair value of stock options granted during the three months ended March 31, 2023 and 2022 was $ 0.56 per share and $ 5.06 per share, respectively. As of March 31, 2023 , total unrecognized compensation expense related to stock options totaled approximately $ 20.3 million, which is expected to be recognized over a weighted-average period of 2.8 years. The aggregate intrinsic value of common stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The intrinsic value of options exercised for the three months ended March 31, 2023 and 2022 , was approximately $ 9 thousand and $ 0.6 million, respectively. Restricted Stock The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company’s common stock on that same date. The Company did not have any restricted stock activity during the three months ended March 31, 2023. The total fair value of restricted stock that vested during the three months ended March 31, 2022 was approximately $ 25 thousand. Stock-Based Compensation Expense Stock-based compensation expense recorded as research and development and general and administrative expenses, for employees, directors and non-employees during the three months ended March 31, 2023 and 2022 is as follows: THREE MONTHS ENDED MARCH 31, 2023 2022 ($ in thousands) Research and development $ 1,308 $ 504 General and administrative 1,000 1,683 Total stock-based compensation expense $ 2,308 $ 2,187 The Company recognized additional stock-based compensation expense associated with 292,650 shares subject to GreenLight options that vest based on both a liquidity and a service condition. At the date of grant in 2020, achievement of the conditions in the performance-based award was deemed not probable and, accordingly, the grant date fair value of the award was zero based upon the probable outcome of such conditions. The liquidity condition is satisfied upon the occurrence of certain events, including a merger or acquisition or other business combination transaction involving the Company and a publicly traded special purpose acquisition company or other similar entity and, as a result, the liquidity condition for certain of GreenLight’s options was satisfied upon the completion of the Business Combination. Assuming achievement of the highest level of performance, the performance-based award would have had a grant date fair value of $ 0.2 million. In December 2021, the Company’s Board of Directors voted to extend the length of time to allow for the performance vesting to occur by March 31, 2022 . The fair value of the award, as modified, was $ 2.1 million as of the modification date. Upon closing of the Business Combination, the Company recognized approximately $ 1.4 million of incremental stock-based compensation expense associated with these options during the three months ended March 31, 2022, and the remainder is being recognized over the remaining service period.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Net Loss Per Share	14. NET LOSS PER SHARE The following table summarizes the computation of basic and diluted net loss per share: (In thousands, except shares and per share data) THREE MONTHS ENDED 2023 2022 Numerator: Net loss $ ( 28,469 ) $ ( 38,207 ) Denominator: Weighted-average common stock outstanding 151,614,008 113,558,404 Net loss per share, basic and diluted $ ( 0.19 ) $ ( 0.34 ) The Company’s potential dilutive securities include unvested restricted stock, common stock options and common stock warrants. The Company excluded the following potential common stock, presented based on amounts outstanding at period end, from the computation of diluted net loss per share because including them would have had an anti-dilutive effect: AS OF MARCH, 2023 2022 Unvested restricted stock — 2,664 Options to purchase common stock 22,431,125 18,505,366 Common stock warrants 12,383,304 12,383,304 Total 34,814,429 30,891,334

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Income Taxes	15. INCOME TAXES The Company did no t record U.S. federal, state or foreign income tax expense for the three months ended March 31, 2023 and 2022 due to the Company’s historical net operating losses, forecasted continued net operating losses, and the Company’s recognition of a full valuation allowance. The Company's effective tax rate differs from the statutory rate, primarily due to the Company’s history of incurring losses, which have not been benefited, other permanent differences, and withholding taxes. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	16. LEASES The Company adopted Accounting Standards Codification ("ASC") 842, Leases, during the quarter ended December 31, 2022, with an effective date of January 1, 2022, using the modified retrospective approach and utilizing the effective date as its date of initial application. The Company's condensed consolidated financial statements presented for fiscal year 2022 have been adjusted to reflect the impact of adoption of ASC 842 as of the effective date of January 1, 2022 . As a result of implementing this guidance, the Company recorded an operating right-of-use asset of $ 15.2 million and an operating lease liabilities of $ 15.9 million, respectively, as of January 1, 2022 and also derecognized total deferred rent liabilities and unamortized lease incentives of $ 0.7 million that existed as of December 31, 2021. The adoption of this standard did not have a significant impact on the Company’s Consolidated Statements of Operations as of December 31, 2022. As of March 31, 2022 the adoption of ASC 842 resulted in the recognition of operating lease right-of-use assets of $ 31.7 million and current and noncurrent operating lease liabilities of $ 6.3 million and $ 26.8 million, respectively, on the Company’s condensed consolidated balance sheet. The adoption of ASC 842 for the three months ended March 31, 2022 resulted in an impact to the condensed consolidated statement of cash flows of an increase of $ 1.6 million in other non-cash operating lease cost, a net change in accrued expenses, lease liabilities and other liabilities of $ 1.4 million and deferred rent of $ 0.3 million. The adoption of ASC 842 had no material impact to the condensed consolidated statement of operations for the three months ended March 31, 2022. The Company leases certain laboratory and office spaces under operating leases and certain equipment under financing leases. Determination if an arrangement is a lease occurs at inception. For leases with terms greater than 12 months, the Company records a related right-of-use (“ROU”) asset and lease liability at the present value of lease payments over the term. Many leases include fixed rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when appropriate. The Company’s leases generally do not provide an implicit rate, and thus the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has elected not to record a ROU asset and lease obligation for short-term leases (with terms less than 12 months) or separate non-lease components from associated lease components for all asset classes. As a result, all contract consideration is allocated to the single lease component. The Company leases certain of its facilities under non-cancellable operating and financing leases expiring at various dates through 2042. The Company is also responsible for utilities, maintenance, insurance, and property taxes under these leases which are variable payments. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms. We often receive customary incentives from our landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases. Leases are classified as operating or financing at commencement. Certain leases include options to renew or terminate at the Company’s discretion. The lease terms include periods covered by these options if it is reasonably certain the Company will renew or not terminate. The following table reconciles the right of use operating and finance leases and corresponding liabilities to the balance sheet as of March 31, 2023 and December 31, 2022, respectively (in thousands): CLASSIFICATION ON THE CONDENSED CONSOLIDATED BALANCE SHEET MARCH 31, 2023 DECEMBER 31, 2022 Assets: Right of use asset - operating lease Right-of-use assets $ 32,740 $ 32,766 Right of use asset - financing lease Property and equipment, net 469 519 Total lease assets $ 33,209 $ 33,285 Liabilities: Current: Operating lease liabilities, current Lease liabilities, current portion 4,083 3,358 Finance lease liabilities, current Long-term debt, current portion 134 210 Non-current: Operating lease liabilities, net of current portion Lease liabilities, net of current portion 48,702 49,569 Finance lease liabilities, net of current portion Long-term debt, net of current portion 22 28 Total lease liabilities $ 52,941 $ 53,165 The following table provides the components of the Company's lease costs for the three months ended March 31, 2023 and 2022, respectively (in thousands): THREE MONTHS ENDED MARCH 31 2023 2022 Operating lease costs $ 2,498 $ 2,519 Short-term lease costs 8 140 Variable lease costs 764 86 Total operating lease costs $ 3,270 $ 2,745 Finance lease costs: Amortization of right-of-use assets 50 47 Interest on lease liabilities 3 6 Total finance lease costs $ 53 $ 53 Total lease costs $ 3,323 $ 2,798 Other information related to leases for the three months ended March 31, 2023 and 2022, respectively were as follows (in thousands): THREE MONTHS ENDED MARCH 31 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 2,470 $ 2,040 Operating cash flows for finance leases 3 6 Finance cash flows for finance leases 83 160 Right-of-use assets obtained in exchange for operating lease liabilities $ 791 $ 18,100 Operating Leases Weighted average remaining lease term (years) 9.33 9.08 Weighted average incremental borrowing rate 11.16 % 11.09 % Finance Leases Weighted average remaining lease term (years) 0.75 1.33 Weighted average incremental borrowing rate 7.67 % 5.75 % A summary of the Company's future minimum lease payments under noncancelable leases as of March 31, 2023, is as follows: MARCH 31, 2023 OPERATING LEASES FINANCE LEASES ($ in thousands) Remainder of 2023 $ 6,828 $ 130 2024 9,568 32 2025 8,280 — 2026 8,204 — 2027 8,185 — Thereafter 46,183 — Total future minimum lease payments 87,248 162 Less: imputed interest ( 34,463 ) ( 6 ) Total $ 52,785 $ 156

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
COMMITMENTS AND CONTINGENCIES	17. COMMITMENTS AND CONTINGENCIES Legal proceedings Legal claims may arise from time to time in the normal course of business. There are no such claims during the respective three months ended March 31, 2023 and 2022, that are expected to have a material effect on the Company’s condensed consolidated financial statements. Other funding commitments In December 2020, the Company entered into an assignment and license agreement with Bayer CropScience LLP (“Bayer”) under which the Company may be obligated to make milestone and royalty payments. These payment obligations are contingent upon future events, such as achieving certain development, regulatory, and commercial milestones or generating product sales. The timing of these events is uncertain; accordingly, the Company cannot predict the period during which these payments may become due. The Company has agreed to pay up to $ 2.0 million in milestone payments under this assignment and license agreement when certain development milestones are met. The Company assessed the milestones for the three months ended March 31, 2023 and concluded no such milestone payments were deemed probable nor due. In November 2021, the Company entered into a manufacturing and development contract service agreement with a contract development and manufacturing organization for the Company’s mRNA COVID-19 vaccine. Based on the Company’s minimum purchase commitments, the Company expects to pay the organization a minimum of approximately $ 8.8 million in service fees under the agreement, excluding the cost of raw materials. The Company has incurred $ 5.9 million in costs under this service arrangement for the year ended December 31, 2022, with the remainder in 2023. For the three months ended March 31, 2023, the Company did incur any costs under this service agreement.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
RELATED PARTY TRANSACTIONS	18. RELATED PARTY TRANSACTIONS The Company is party to a Lease Agreement (the “Farmland Lease”) with Mendocino View Farm, LLC, which is a wholly-owned subsidiary of Fall Line Endurance Fund, LP (“Fall Line”). Fall Line is a greater than 5 % shareholder of the Company and Eric O’Brien, a director on the Company’s Board of Directors, is the co-founder and Managing Director of Fall Line. Pursuant to the terms of the Farmland Lease, the Company is leasing approximately 81.25 acres of farmland for research and development purposes at an annual rental rate of $ 0.1 million plus operating expenses. The initial term of the Farmland Lease is ten years , which commenced on January 1, 2023 , subject to an option to extend for an additional ten years . Under the Farmland Lease, the Company agreed to pay $ 0.4 million as additional rent, payable in two installments of $ 0.2 million on each of January 1, 2023 and January 1, 2024. Fall Line provided the Company an allowance of $ 0.1 million towards tenant improvements. Either party under the Farmland Lease may terminate the Farmland Lease subject to a termination fee of $ 0.2 million. Finally, the Company has a right of first offer to purchase the leased farmland in the event Fall Line intends to sell all or any portion of the leased farmland.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	3 Months Ended
	Mar. 31, 2023
Accounting Policies, by Policy (Policies) [Line Items]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development costs, the fair values of common stock (as defined below), useful lives assigned to property and equipment, and the fair value of warrant liabilities. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company has no significant off-balance sheet credit risk. Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, restricted cash and accounts receivable. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Concentration of credit risk with respect to accounts receivable is limited to customers with whom the Company has entered into collaboration agreements. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver and SVB was subsequently transferred into a new entity, Silicon Valley Bridge Bank, N.A (“SVB Bridge Bank”). On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors’ insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its full deposits with SVB Bridge Bank. On March 27, 2023, First Citizens Bank & Trust Company assumed all of SVB's deposits and loans. In light of the foregoing, the Company does not believe that it has exposure to loss as a result of SVB's receivership. As of March 31, 2023, the Company held $ 18.6 million in SVB and has not experienced any losses on its deposits of cash, cash equivalents and restricted cash.
Leases	Leases The Company determines if an arrangement is a lease or contains a lease at inception. Our lease agreements are generally for office and laboratory facilities under operating leases and certain equipment under financing leases, and the determination of whether such agreements contain leases generally does not require significant estimates or judgments. Our leases may also contain non-lease components such as payments of maintenance, utilities, and taxes, which we have elected to account for separately, as these amounts are readily determinable. For leases with terms greater than 12 months, the Company records a related right-of-use (“ROU”) asset and lease liability at the present value of lease payments over the term, discounted using our incremental borrowing rate (“IBR”) over the lease term (or, if readily determinable, the rate implicit in the lease). Many leases include fixed rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when appropriate. The right-of-use asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred and excludes lease incentives. The lease term used to measure right-of-use lease assets and lease liabilities may include renewal options which are deemed reasonably certain to be exercised. Operating lease costs are recognized on a straight-line basis over the lease term. Variable lease payments are expensed as incurred.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. This new standard is effective for the Company in the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company adopted ASU 2016-03 as of January 1, 2023 , with no impact on our condensed consolidated financial statements or the related disclosures.

Business Combination (Tables)

Business Combination (Tables)	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Summary of Reconciles Elements of Business Combination	The following table reconciles the elements of the Business Combination to the Condensed Consolidated Statements of Cash Flows and the Condensed Consolidated Statements of Stockholders’ Defic it: BUSINESS COMBINATION Cash - ENVI trust and cash (net of redemptions) $ 12,123 Cash - PIPE Investors, including proceeds from conversion of Convertible notes - PIPE Investors 124,250 Gross proceeds 136,373 Less: total transaction costs ( 26,660 ) Less: cash proceeds from Convertible notes - PIPE Investors ( 35,250 ) Add: transaction costs paid in 2021 4,080 Cash proceeds from Business Combination received in 2022 78,543 Less: transaction costs paid in 2021 ( 4,080 ) Less: warrant liabilities assumed ( 1,341 ) Less: net liabilities assumed in the Business Combination ( 133 ) Reverse merger, net of transactions costs $ 72,989
Schedule of Number of Shares of Common Stock Outstanding and Immediately Consummation of Business Combination	The number of shares of common stock outstanding immediately following the consummation of the Business Combination was as follows: Number of Shares Common stock, outstanding prior to the Business Combination 20,700,000 Less: Redemption of ENVI shares ( 19,489,626 ) ENVI Public Shares 1,210,374 ENVI Sponsor Shares 5,175,000 Shares issued in PIPE financing 12,425,000 Business combination and PIPE financing shares 18,810,374 Legacy GreenLight shares (1) 104,011,760 Total shares of common stock immediately after Business Combination 122,822,134 (1) - The number of Legacy GreenLight shares was determined from the shares of Legacy GreenLight outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio. All fractional shares were rounded down.

Fair Value Measurements (Tables

Fair Value Measurements (Tables) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Schedule of assets and liabilities at fair value on a recurring basis	The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2023 and December 31, 2022: DESCRIPTION MARCH 31, 2023 QUOTED PRICES SIGNIFICANT SIGNIFICANT ($ in thousands) Asset Money market funds $ 32,350 $ 32,350 $ — $ — Total assets measured at fair value $ 32,350 $ 32,350 $ — $ — Liability Warrant liabilities $ 15 $ — $ — $ 15 Total liabilities measured at fair value $ 15 $ — $ — $ 15 DESCRIPTION DECEMBER 31, QUOTED PRICES SIGNIFICANT SIGNIFICANT ($ in thousands) Asset Money market funds $ 68,097 $ 68,097 $ — $ — Total assets measured at fair value $ 68,097 $ 68,097 $ — $ — Liability Warrant liabilities $ 242 $ — $ — $ 242 Total liabilities measured at fair value $ 242 $ — $ — $ 242
Schedule of changes in the fair value of Level 3 warrant liabilities	The following table presents a roll-forward of the aggregate fair values of the Company’s liabilities for which fair value is determined by Level 3 inputs for the three months ended March 31, 2023 (in thousands): WARRANT LIABILITY Balance—December 31, 2022 $ 242 Change in fair value of warrants ( 227 ) Balance—March 31, 2023 $ 15

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Summary of Property and Equipment	Property and equipment, net consisted of the following as of March 31, 2023 and December 31, 2022: MARCH 31, DECEMBER 31, ($ in thousands) Leasehold improvements $ 25,196 $ 25,175 Laboratory equipment 25,162 24,373 Manufacturing and farm equipment 1,495 1,450 Computer hardware and software 1,394 1,338 Furniture and fixtures 702 702 Construction in progress 1,847 1,348 Total 55,796 54,386 Less: Accumulated depreciation and amortization ( 15,355 ) ( 13,021 ) Property and equipment, net $ 40,441 $ 41,365

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2023
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Accrued Liabilities, Current [Line Items]
Summary of Accrued Expenses	Accrued expenses as of March 31, 2023 and December 31, 2022 consisted of the following: MARCH 31, DECEMBER 31, ($ in thousands) Accrued employee compensation and benefits $ 6,304 $ 5,998 Accrued research and development 1,448 3,041 Accrued professional fees 1,281 1,152 Accrued other 2,445 3,353 Total accrued expenses $ 11,478 $ 13,544

Debt (Tables)

Debt (Tables) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	3 Months Ended
	Mar. 31, 2023
Debt Instrument [Line Items]
Summary of the Outstanding Debt	A summary of the outstanding debt as of March 31, 2023 is as follows (in thousands): AS OF MARCH 31, 2023 DESCRIPTION ISSUANCE DATE(S) MATURITY DATE(S) INTEREST RATE PRINCIPAL BALANCE OUTSTANDING UNAMORTIZED DEBT DISCOUNT DEBT BALANCE Trinity Equipment Financing March 2021 - August 2021 March 2024 - August 2024 9.48 % - 9.73 % $ 4,963 $ ( 120 ) $ 4,843 Term Loan – Silicon Valley Bank September 2021 September 2024 8.25 % 6,000 ( 74 ) 5,926 Term Loan – Horizon December 2021 July 2025 13.75 % 14,000 ( 285 ) 13,715 Finance Lease 156 — 156 Total Debt 25,119 ( 479 ) 24,640 Less: current portion ( 13,782 ) Total long-term $ 10,858 A summary of the outstanding debt as of December 31, 2022 is as follows (in thousands): AS OF DECEMBER 31, 2022 DESCRIPTION ISSUANCE DATE(S) MATURITY DATE(S) STATED INTEREST RATE PRINCIPAL BALANCE OUTSTANDING UNAMORTIZED DEBT DISCOUNT DEBT BALANCE Trinity Equipment Financing March 2021 - August 2021 March 2024 - August 2024 9.48 % - 9.73 % $ 5,905 $ ( 146 ) $ 5,759 Term Loan - Silicon Valley Bank September 2021 September 2024 7.75 % 7,000 ( 98 ) 6,902 Term Loan - Horizon December 2021 July 2025 13.25 % 15,000 ( 343 ) 14,657 Finance Lease 237 — 237 Total Debt 28,142 ( 587 ) 27,555 Less: current portion ( 13,229 ) Total long-term $ 14,326
Summary of Interest Expense	Interest expense for the three months ended March 31, 2023 and 2022 consisted of the following: THREE MONTHS ENDED MARCH 31, 2023 2022 ($ in thousands) Interest paid or accrued $ 898 $ 804 Non-cash amortization of debt discount and deferred financing cost 109 224 Total $ 1,007 $ 1,028
Scheduled Future Principal Payments on Total Outstanding Debt	Scheduled future principal payments on total outstanding debt, as of March 31, 2023 are as follows (in thousands): MARCH 31, 2023 Remainder of 2023 $ 10,591 2024 11,028 2025 3,500 Total $ 25,119

Warrants (Tables)

Warrants (Tables) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	3 Months Ended
	Mar. 31, 2023
Class of Warrant or Right [Line Items]
Summary of Roll-forward of the Warrants	The following table presents a summary of the Company’s warrants activity from December 31, 2022 to March 31, 2023: COMMON STOCK WARRANTS Warrants Outstanding, December 31, 2022 12,383,304 Issued — Exercised — Warrants Outstanding, March 31, 2023 12,383,304
Common Stock Warrants Classified as Liability [Member]
Class of Warrant or Right [Line Items]
Summary of Estimated Fair Value of the Warrants	The fair value of the Private Placement Warrants upon initial recognition, as of December 31, 2022 and as of March 31, 2023 was estimated to be approximately $ 1.3 million, $ 0.2 million and $ 15 thousand, respectively, and was measured using a Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AS OF MARCH 31, 2023 AS OF DECEMBER 31, 2022 INITIAL RECOGNITION Fair value of common stock $ 0.43 $ 1.18 $ 8.82 Risk free interest rate 3.70 % 4.05 % 1.59 % Volatility 69.0 % 69.0 % 15.9 % Expected term (in years) 3.75 4.17 5.00
Common Stock Warrants Classified as Equity [Member]
Class of Warrant or Right [Line Items]
Summary of Common Stock Warrants Classified	The warrant issued for the $ 10.0 million available commitment is summarized below as a liability-classified Common Stock Warrant. Warrant Class Shares Inception Date Fair Value (in thousands) Issuance Date Exercise Price Expiration Date Common stock warrant 28,517 $ 249 January 19, 2022 $ 5.26 The earlier of March 29, 2031 or the date of a qualifying acquisition
Summary of Estimated Fair Value of the Warrants	The warrants' fair value upon issuance was estimated to be approximately $ 0.4 million, and was measured using a Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AT ISSUANCE (AS OF JANUARY 19, 2022) Fair value of common stock $ 5.89 Risk free interest rate 1.50 % Expected volatility 59.60 % Expected term (in years) 10.00 The warrant’s fair value upon issuance and as of June 30, 2022 was estimated to be approximately $ 0.2 million and $ 35 thousand, respectively, and was measured using a probability weighted Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AT ISSUANCE (AS OF JANUARY 19, 2022) AS OF Fair value of common stock $ 5.89 $ 2.21 Risk free interest rate 1.50 % 2.39 % Expected volatility 59.60 % 59.60 % Expected term (in years) 10.50 10.00

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Fair Value Assumptions of Stock Option Awards Estimated on Grant Date	The fair value of stock option awards is estimated on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: THREE MONTHS ENDED MARCH 31, 2023 2022 Fair value of underlying common stock $ 0.56 $ 9.15 Weighted average risk-free interest rate 3.89 % 2.56 % Expected term (in years) 6.07 6.00 Expected volatility 56.97 % 56.28 % Expected dividend yield 0.00 % 0.00 %
Summary of Stock Options Activity	The following table summarizes the activity of the Company’s stock options under the Plan for the three months ended March 31, 2023: AVERAGE AGGREGATE WEIGHTED- REMAINING INTRINSIC AVERAGE CONTRACTUAL VALUE SHARES EXERCISE PRICE TERM (in years) (in thousands) Outstanding at December 31, 2022 23,051,188 $ 2.35 7.8 $ 7,192 Granted 229,500 0.97 — — Exercised ( 94,149 ) 0.37 — — Cancelled or forfeited ( 755,414 ) 3.11 — — Outstanding at March 31, 2023 22,431,125 2.25 7.6 355 Vested and expected to vest at March 31, 2023 22,431,125 2.25 7.6 355 Exercisable at March 31, 2023 11,015,527 $ 1.11 6.3 $ 333
Summary of Stock-Based Compensation Expense	Stock-based compensation expense recorded as research and development and general and administrative expenses, for employees, directors and non-employees during the three months ended March 31, 2023 and 2022 is as follows: THREE MONTHS ENDED MARCH 31, 2023 2022 ($ in thousands) Research and development $ 1,308 $ 504 General and administrative 1,000 1,683 Total stock-based compensation expense $ 2,308 $ 2,187

Net Loss Per Share (Tables)

Net Loss Per Share (Tables) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	3 Months Ended
	Mar. 31, 2023
Summary of the computation of basic and diluted net loss per share	The following table summarizes the computation of basic and diluted net loss per share: (In thousands, except shares and per share data) THREE MONTHS ENDED 2023 2022 Numerator: Net loss $ ( 28,469 ) $ ( 38,207 ) Denominator: Weighted-average common stock outstanding 151,614,008 113,558,404 Net loss per share, basic and diluted $ ( 0.19 ) $ ( 0.34 )
Summary of the excluded potential common stock	The Company’s potential dilutive securities include unvested restricted stock, common stock options and common stock warrants. The Company excluded the following potential common stock, presented based on amounts outstanding at period end, from the computation of diluted net loss per share because including them would have had an anti-dilutive effect: AS OF MARCH, 2023 2022 Unvested restricted stock — 2,664 Options to purchase common stock 22,431,125 18,505,366 Common stock warrants 12,383,304 12,383,304 Total 34,814,429 30,891,334

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of Reconciles the Right of Use Operating and Finance Leases and Corresponding to the Balance Sheet	The following table reconciles the right of use operating and finance leases and corresponding liabilities to the balance sheet as of March 31, 2023 and December 31, 2022, respectively (in thousands): CLASSIFICATION ON THE CONDENSED CONSOLIDATED BALANCE SHEET MARCH 31, 2023 DECEMBER 31, 2022 Assets: Right of use asset - operating lease Right-of-use assets $ 32,740 $ 32,766 Right of use asset - financing lease Property and equipment, net 469 519 Total lease assets $ 33,209 $ 33,285 Liabilities: Current: Operating lease liabilities, current Lease liabilities, current portion 4,083 3,358 Finance lease liabilities, current Long-term debt, current portion 134 210 Non-current: Operating lease liabilities, net of current portion Lease liabilities, net of current portion 48,702 49,569 Finance lease liabilities, net of current portion Long-term debt, net of current portion 22 28 Total lease liabilities $ 52,941 $ 53,165
Schedule of Lease Cost	The following table provides the components of the Company's lease costs for the three months ended March 31, 2023 and 2022, respectively (in thousands): THREE MONTHS ENDED MARCH 31 2023 2022 Operating lease costs $ 2,498 $ 2,519 Short-term lease costs 8 140 Variable lease costs 764 86 Total operating lease costs $ 3,270 $ 2,745 Finance lease costs: Amortization of right-of-use assets 50 47 Interest on lease liabilities 3 6 Total finance lease costs $ 53 $ 53 Total lease costs $ 3,323 $ 2,798
Schedule of Other Information Related To Leases	Other information related to leases for the three months ended March 31, 2023 and 2022, respectively were as follows (in thousands): THREE MONTHS ENDED MARCH 31 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 2,470 $ 2,040 Operating cash flows for finance leases 3 6 Finance cash flows for finance leases 83 160 Right-of-use assets obtained in exchange for operating lease liabilities $ 791 $ 18,100 Operating Leases Weighted average remaining lease term (years) 9.33 9.08 Weighted average incremental borrowing rate 11.16 % 11.09 % Finance Leases Weighted average remaining lease term (years) 0.75 1.33 Weighted average incremental borrowing rate 7.67 % 5.75 %
Summary of Future Minimum Lease Payments Under Non-cancelable Leases	A summary of the Company's future minimum lease payments under noncancelable leases as of March 31, 2023, is as follows: MARCH 31, 2023 OPERATING LEASES FINANCE LEASES ($ in thousands) Remainder of 2023 $ 6,828 $ 130 2024 9,568 32 2025 8,280 — 2026 8,204 — 2027 8,185 — Thereafter 46,183 — Total future minimum lease payments 87,248 162 Less: imputed interest ( 34,463 ) ( 6 ) Total $ 52,785 $ 156

Nature of Business and Basis _2

Nature of Business and Basis of Presentation (Details)		3 Months Ended
	Feb. 02, 2022 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares shares	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Description of Organization and Business Operations (Details) [Line Items]
Net Income Loss		$ (28,469,000)	$ (38,207,000)
Net Cash Provided by (Used in) Operating Activities		(31,060,000)	(49,511,000)
Cash and cash equivalents		32,350,000	$ 83,223,000	$ 68,097,000
Accumulated deficit		$ (449,107,000)		$ (420,638,000)
Warrants outstanding | shares		12,383,304		12,383,304
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
PIPE [Member]
Description of Organization and Business Operations (Details) [Line Items]
Proceeds from divestiture of businesses	$ 136,400,000
Cash Acquired Net of Redemption		$ 109,700,000
Legacy Green Light [Member]
Description of Organization and Business Operations (Details) [Line Items]
Business combination exchange ratio	0.6656
Business combination transaction costs		$ 26,700,000
Goodwill	$ 0
Intangible assets	$ 0
Legacy Green Light [Member] | PIPE [Member]
Description of Organization and Business Operations (Details) [Line Items]
Purchase price					$ 21,800,000	$ 13,500,000
Public Warrants [Member]
Description of Organization and Business Operations (Details) [Line Items]
Warrants outstanding | shares	10,350,000
Exercise Price | $ / shares	$ 11.50
Private Placement Warrants [Member]
Description of Organization and Business Operations (Details) [Line Items]
Warrants outstanding | shares	2,062,500
Exercise Price | $ / shares	$ 11.50
Public and Private Placement Warrants [Member]
Description of Organization and Business Operations (Details) [Line Items]
Warrants expiration period	5 years
Class A Common Stock | Legacy Green Light [Member]
Description of Organization and Business Operations (Details) [Line Items]
Common stock, par value | $ / shares	$ 0.0001
Class A Common Stock | Legacy Green Light [Member] | PIPE [Member]
Description of Organization and Business Operations (Details) [Line Items]
Purchase price	$ 124,300,000
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Description of Organization and Business Operations (Details) [Line Items]
Common stock, par value | $ / shares		$ 0.0001		$ 0.0001
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Class A Common Stock | Legacy Green Light [Member]
Description of Organization and Business Operations (Details) [Line Items]
Purchase price | shares	12,425,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Summary of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 32,350	$ 68,097	$ 83,223
SVB Bridge Bank [Member]
Summary of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 18,600
ASU 2016-13 [Member]
Summary of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2023
Change in accounting principle, accounting standards update, immaterial effect	true

Business Combination - Addition

Business Combination - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Feb. 02, 2022
Authorized shares capital				510,000,000
Common stock, shares authorized	500,000,000	500,000,000		500,000,000
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000		10,000,000
Warrant liabilities	$ 15	$ 242
Private Placement Warrants [Member]
Warrant liabilities				$ 1,300
Shares issued				2,062,500
Public Warrants [Member]
Shares issued				10,350,000

Business Combination - Summary

Business Combination - Summary of Reconciles Elements of Business Combination (Details) - USD ($) $ in Thousands		3 Months Ended
	Feb. 02, 2022	Mar. 31, 2022
Business Acquisition [Line Items]
Gross Proceeds	$ 136,373
Less: total transaction costs	(26,660)
Add: transaction costs paid in 2021	4,080
Cash proceeds from Business Combination received in 2022	78,543
Less: transaction costs paid in 2021	(4,080)
Less: warrant liabilities assumed	(1,341)	$ (1,341)
Less: net liabilities assumed in the Business Combination	(133)
Reverse merger, net of transactions costs	72,989
ENVI Trust [Member]
Business Acquisition [Line Items]
Cash (net of redemption)	12,123
PIPE Investors [Member]
Business Acquisition [Line Items]
Cash (net of redemption)	124,250
Less: cash proceeds from Convertible notes - PIPE Investors	$ (35,250)

Business Combination - Schedule

Business Combination - Schedule of Number of Shares of Common Stock Outstanding Immediately Consummation of Business Combination (Details) - shares	Mar. 31, 2023	Dec. 31, 2022	Feb. 02, 2022
Business Acquisition [Line Items]
Common stock, outstanding prior to the Business Combination			20,700,000
Less: Redemption of ENVI shares			(19,489,626)
Shares issued in PIPE financing			12,425,000
Business combination and PIPE financing shares			18,810,374
Total shares of common stock immediately after business combination	151,681,314	151,587,165	122,822,134
ENVI Public Shares [Member]
Business Acquisition [Line Items]
Shares issued			1,210,374
ENVI Sponsor Shares [Member]
Business Acquisition [Line Items]
Shares issued			5,175,000
Legacy GreenLight Equityholders [Member]
Business Acquisition [Line Items]
Total shares of common stock immediately after business combination			104,011,760

License Agreement - Additional

License Agreement - Additional Information (Detail) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Jan. 31, 2021	Aug. 31, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Development Costs, Period Cost						$ 500,000
Research and Development Expense			$ 400,000	$ 300,000
First Non Exclusive License [Member]
License Fee		$ 1,500,000
Second Non Exclusive License [Member]
License Fee		1,800,000
Third Non Exclusive License [Member]
License Fee		2,800,000
Acuitas Therapeutics Inc [Member]
Technology Access Fee		800,000
Management Fee Expense		$ 100,000
Option exercise fee	$ 1,500,000
Research and Development Expense			$ 0		$ 0
Acuitas Therapeutics Inc [Member] | Target One And Two [Member]
Annual license maintenance fee	1,000,000
Acuitas Therapeutics Inc [Member] | Target Three [Member]
Annual license maintenance fee	$ 800,000

License and Collaboration Agr_2

License and Collaboration Agreements - Additional Information (Details)	1 Months Ended	3 Months Ended
	Mar. 31, 2022 Product	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and collaboration revenue		$ 3,820,000	$ 0
Collaborative Arrangement [Member] | SIIPL [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement date	2022-03
Initial license agreement for number of products | Product	3
Option to increase license agreement for number of products | Product	2
Option to purchase developed research plan and clinical trial data for percentage of actual cost	50%
Upfront license fee to be received		5,000,000
Collaborative arrangement aggregate milestone receivable		17,000,000
Maximum manufacturing technology transfer payments to be received		10,000,000
Maximum development and regulatory payments to be received		17,000,000
Manufacturing technology transfer payment to be fully constrained		5,000,000
License and collaboration revenue		$ 3,800,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of assets and liabilities at fair value on a recurring basis - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets:
Total assets measured at fair value	$ 32,350	$ 68,097
Liabilities:
Warrant liabilities	15	242
Total liabilities measured at fair value	15	242
Money Market Funds [Member]
Assets:
Money market funds	32,350	68,097
Level 1 [Member]
Assets:
Total assets measured at fair value	32,350	68,097
Liabilities:
Warrant liabilities	0	0
Total liabilities measured at fair value	0	0
Level 1 [Member] | Money Market Funds [Member]
Assets:
Money market funds	32,350	68,097
Level 3 [Member]
Assets:
Total assets measured at fair value	0	0
Liabilities:
Warrant liabilities	15	242
Total liabilities measured at fair value	15	242
Level 3 [Member] | Money Market Funds [Member]
Assets:
Money market funds	0	0
Level 2 [Member]
Assets:
Total assets measured at fair value	0	0
Liabilities:
Warrant liabilities	0	0
Total liabilities measured at fair value	0	0
Level 2 [Member] | Money Market Funds [Member]
Assets:
Money market funds	$ 0	$ 0

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Fair Value Measurements (Details) [Line Items]
Fair value of equipment financing	$ 4,800,000
Carrying value of equipment financing	5,000,000
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Fair Value Measurements (Details) [Line Items]
Carrying value of equipment financing	25,119,000		$ 28,142,000
Fair Value, Inputs, Level 1, 2 and 3 [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Fair Value Measurements (Details) [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net	$ 0	$ 0

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of changes in the fair value of Level 3 warrant liabilities - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value beginning	$ 242
Change in fair value of warrants	$ (227)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Unrealized Gain (Loss) on Derivatives
Fair value ending	$ 15

Grant Revenue - Additional Info

Grant Revenue - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 31, 2020
Grant Revenue [Line Items]
Grant revenue	$ 0	$ 257,000
Deferred revenue	47,000		$ 3,866,000
Other current liabilities	724,000		$ 724,000
Bill and Melinda Gates Foundation [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Grant Revenue [Line Items]
Grant receivable						$ 3,300,000
Aggregate grant received				$ 900,000	$ 2,400,000
Research and developments costs associated with grant	0	300,000
Grant revenue		$ 300,000
Other current liabilities	$ 800,000

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 40,441	$ 41,365
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	55,796	54,386
Less: Accumulated depreciation and amortization	(15,355)	(13,021)
Property and equipment, net	40,441	41,365
Leasehold improvements [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,196	25,175
Laboratory equipment [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,162	24,373
Manufacturing and farm equipment [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,495	1,450
Computer hardware and software [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,394	1,338
Furniture and fixtures [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	702	702
Construction in progress [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,847	$ 1,348

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Capital lease assets	$ 2.6		$ 2.6
Capital lease accumulated amortization	2.1		$ 2
Depreciation and amortization expense	$ 2.3	$ 2.1

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued Liabilities, Current [Line Items]
Total accrued expenses	$ 11,478	$ 13,544
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Accrued Liabilities, Current [Line Items]
Accrued employee compensation and benefits	6,304	5,998
Accrued research and development	1,448	3,041
Accrued professional fees	1,281	1,152
Accrued other	2,445	3,353
Total accrued expenses	$ 11,478	$ 13,544

Debt - Summary of Outstanding D

Debt - Summary of Outstanding Debt (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal Balance Outstanding	$ 5,000
Finance Lease, Debt Balance	156
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Debt Instrument [Line Items]
Principal Balance Outstanding	25,119	$ 28,142
Unamortized Debt Discount	(479)	(587)
Debt Balance	24,640	27,555
Finance Lease, Principal Balance	156	237
Finance Lease, Debt Balance	156	237
Less: current Portion	(13,782)	(13,229)
Total long-term	$ 10,858	$ 14,326
Trinity Equipment Financing [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Debt Instrument [Line Items]
Issuance Date(s)	March 2021 - August 2021	March 2021 - August 2021
Maturity Date(s)	March 2024 - August 2024	March 2024 - August 2024
Principal Balance Outstanding	$ 4,963	$ 5,905
Unamortized Debt Discount	(120)	(146)
Debt Balance	$ 4,843	$ 5,759
Trinity Equipment Financing [Member] | Maximum [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Debt Instrument [Line Items]
Stated Interest Rate	9.73%	9.73%
Trinity Equipment Financing [Member] | Minimum [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Debt Instrument [Line Items]
Stated Interest Rate	9.48%	9.48%
Silicon Valley Bank Term Loan [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Debt Instrument [Line Items]
Issuance Date(s)	September 2021	September 2021
Maturity Date(s)	September 2024	September 2024
Stated Interest Rate	8.25%	7.75%
Principal Balance Outstanding	$ 6,000	$ 7,000
Unamortized Debt Discount	(74)	(98)
Debt Balance	$ 5,926	$ 6,902
Horizon Term Loan [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Debt Instrument [Line Items]
Issuance Date(s)	December 2021	December 2021
Maturity Date(s)	July 2025	July 2025
Stated Interest Rate	13.75%	13.25%
Principal Balance Outstanding	$ 14,000	$ 15,000
Unamortized Debt Discount	(285)	(343)
Debt Balance	$ 13,715	$ 14,657

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands

1 Months Ended

3 Months Ended

Feb. 02, 2022

Mar. 29, 2021

Feb. 28, 2022

Jan. 31, 2022

Dec. 31, 2021

Mar. 31, 2023

Mar. 31, 2022

Sep. 01, 2024

Sep. 22, 2023

Aug. 01, 2023

Dec. 31, 2022

Sep. 22, 2022

Dec. 01, 2021

Sep. 01, 2021

Debt Instrument [Line Items]

Convertible instruments, surrendered and cancelled

$ 2,941

$ 815

Debt instrument, Carrying amount

$ 5,000

Horizon Term Loan [Member]

Debt Instrument [Line Items]

Debt Instrument Unused Borrowing Capacity

$ 10,000

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]

Debt Instrument [Line Items]

Debt Instrument Final Payment Fee Charged As Percentage Of Principal Amount

3%

Debt instrument, Carrying amount

$ 25,119

$ 28,142

Accrued interest

$ 1,600

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Series D Preferred Stock [Member]

Debt Instrument [Line Items]

Debt conversion, converted instrument, shares issued

10,100,000

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Warrant [Member] | Master Equipment Financing Agreement [Member] | Equipment Financing [Member]

Debt Instrument [Line Items]

Fair Value Of warrants In Debt Issuance Cost

100

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Trinity Capital [Member] | Master Equipment Financing Agreement [Member] | Equipment Financing [Member]

Debt Instrument [Line Items]

Debt instrument Current Borrowings Capacity

$ 5,000

Proceeds from Issuance of Debt

$ 400

Warrants to purchase shares of common stock issued

146,325

Long Term Debt

$ 11,300

Interest Rate

3.25%

Debt Instrument Advances Drawn

$ 11,300

Long-term debt repayment period in months

36

Debt instrument, Carrying amount

$ 14,700

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Scenario Forecast [Member] | Prepayment Year One [Member]

Debt Instrument [Line Items]

Long Term Debt Prepayment Amount As A Percentage Of Principal

3%

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Scenario Forecast [Member] | Prepayment Year Two [Member]

Debt Instrument [Line Items]

Long Term Debt Prepayment Amount As A Percentage Of Principal

2%

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Scenario Forecast [Member] | Prepayment Year Three [Member]

Debt Instrument [Line Items]

Long Term Debt Prepayment Amount As A Percentage Of Principal

1%

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Horizon Term Loan [Member]

Debt Instrument [Line Items]

Debt Instrument Maturity Date

Feb. 01, 2023

Debt Instrument Maturity Date

Jul. 01, 2025

Proceeds from Issuance of Debt

$ 600

Debt instrument, Carrying amount

14,000

15,000

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Horizon Term Loan [Member] | Warrant [Member]

Debt Instrument [Line Items]

Fair Value Of warrants In Debt Issuance Cost

400

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Horizon Term Loan [Member] | Horizon Technology Finance Corporation [Member] | Powerscourt Investments XXV, LP (Horizon) [Member]

Debt Instrument [Line Items]

Long Term Debt

$ 25,000

Debt instrument Current Borrowings Capacity

$ 15,000

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member]

Debt Instrument [Line Items]

Debt Instrument Unused Borrowing Capacity

$ 5,000

Debt Instrument Maturity Date

Apr. 01, 2022

Debt Instrument Maturity Date

Sep. 01, 2024

Debt Instrument Final Payment Fee Charged As Percentage Of Principal Amount

4%

Proceeds from Issuance of Debt

$ 300

Warrants to purchase shares of common stock issued

34,427

Debt Issuance Cost

$ 400

Debt instrument, Carrying amount

6,000

$ 7,000

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Warrant [Member]

Debt Instrument [Line Items]

Fair Value Of warrants In Debt Issuance Cost

$ 200

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Prepayment Year One [Member]

Debt Instrument [Line Items]

Long Term Debt Prepayment Amount As A Percentage Of Principal

3%

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Silicon Valley Bank [Member] | Loan And Security Agreement [Member]

Debt Instrument [Line Items]

Long Term Debt

$ 15,000

Debt instrument Current Borrowings Capacity

$ 10,000

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Scenario Forecast [Member] | Prepayment Year Two [Member]

Debt Instrument [Line Items]

Long Term Debt Prepayment Amount As A Percentage Of Principal

2%

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Scenario Forecast [Member] | Prepayment Year Three [Member]

Debt Instrument [Line Items]

Long Term Debt Prepayment Amount As A Percentage Of Principal

1%

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Two Thousand And Twenty One PIPE Notes [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Proceeds from convertible debt

$ 21,800

13,500

Debt instrument, principal amount

$ 35,300

Convertible instruments, surrendered and cancelled

$ 35,300

GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Two Thousand And Twenty Notes [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Convertible notes

$ 16,800

Debt - Summary Of Interest Expe

Debt - Summary Of Interest Expense (Detail) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule Of Interest Expense Debt [Line Items]
Interest paid or accrued	$ 898	$ 804
Non-cash amortization of debt discount and deferred financing cost	109	224
Total	$ 1,007	$ 1,028

Debt - Summary Of Future Princi

Debt - Summary Of Future Principal Payment Of Long Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Schedule Of Maturities Of Long Term Debt [Line Items]
Debt Balance	$ 5,000
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Schedule Of Maturities Of Long Term Debt [Line Items]
Remainder of 2023	10,591
2024	11,028
2025	3,500
Debt Balance	$ 25,119	$ 28,142

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 19, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Feb. 02, 2022
Class of Warrant or Right Exercised During Period
Warrants outstanding			12,383,304			12,383,304
Exercise of public warrants				$ 1,209
Common Stock Warrants [Member]
Class of Warrant or Right Exercised During Period
Warrants outstanding			12,383,304			12,383,304
Private Placement Warrants [Member]
Class of Warrant or Right Exercised During Period
Warrants outstanding									2,062,500
Class of warrant or right, number of securities called by warrants or rights									2,062,500
Exercise Price									$ 11.50
Public Warrants [Member]
Class of Warrant or Right Exercised During Period
Warrants outstanding									10,350,000
Class of warrant or right, number of securities called by warrants or rights									10,350,000
Exercise Price									$ 11.50
Public warrants exercises		105,120
Exercise of public warrants		$ 1,200
Common Stock Warrant Classified As Liability [Member] | Common Stock Warrants [Member]
Class of Warrant or Right Exercised During Period
Exercise Price	$ 5.26
Estimated fair value of warrant upon initial recognition	$ 200							$ 35
Common Stock Warrant Classified As Liability [Member] | Private Placement Warrants [Member]
Class of Warrant or Right Exercised During Period
Warrants outstanding			2,062,500						2,062,500
Class of warrant or right, number of securities called by warrants or rights			2,062,500						2,062,500
Exercise Price			$ 0.43			$ 1.18			$ 8.82
Estimated fair value of warrant upon initial recognition			$ 15			$ 200			$ 1,300
Common Stock Warrants Classified As Equity [Member]
Class of Warrant or Right Exercised During Period
Description of redemption of public warrants			The Company may elect to redeem the Public Warrants subject to certain conditions, in whole and not in part, at a price of $0.01 per Public Warrant if (i) 30 days’ prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis.
Common Stock Warrants Classified As Equity [Member] | Common Stock Warrants [Member]
Class of Warrant or Right Exercised During Period
Estimated fair value of warrant upon initial recognition	$ 400
Fair value warrants reclassified to equity		$ 400		$ 400				$ 35
Common Stock Warrants Classified As Equity [Member] | Public Warrants [Member]
Class of Warrant or Right Exercised During Period
Warrants outstanding			10,350,000
Class of warrant or right, number of securities called by warrants or rights			10,350,000
Exercise Price							$ 11.50
Redemption price per public warrant			$ 0.01
Common Stock Warrants Classified As Equity [Member] | Public Warrants [Member] | Minimum [Member]
Class of Warrant or Right Exercised During Period
Redemption price per public warrant			$ 18
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Class of Warrant or Right Exercised During Period
Warrants issued	28,517
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant Classified As Liability [Member] | Common Stock Warrants [Member]
Class of Warrant or Right Exercised During Period
Class of warrant or right, number of securities called by warrants or rights	57,034
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants Classified As Equity [Member] | Common Stock Warrants [Member]
Class of Warrant or Right Exercised During Period
Class of warrant or right, number of securities called by warrants or rights	85,552
Exercise Price	$ 5.26
Horizon Term Loan [Member]
Class of Warrant or Right Exercised During Period
Debt instrument, Remaining borrowing capacity					$ 10,000
Horizon Term Loan [Member] | Common Stock Warrant Classified As Liability [Member]
Class of Warrant or Right Exercised During Period
Debt instrument Current Borrowings Capacity					10,000
Proceeds from term loan facility					15,000
Debt instrument, Remaining borrowing capacity					10,000
Horizon Term Loan [Member] | Common Stock Warrant Classified As Liability [Member] | Maximum [Member]
Class of Warrant or Right Exercised During Period
Long-term debt					$ 25,000
Horizon Term Loan [Member] | Common Stock Warrants Classified As Equity [Member]
Class of Warrant or Right Exercised During Period
Debt instrument, Remaining borrowing capacity	$ 15,000
Horizon Term Loan [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Class of Warrant or Right Exercised During Period
Proceeds from term loan facility			$ 600

Warrants - Summary of Common St

Warrants - Summary of Common Stock Warrants Classified (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 19, 2022	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Feb. 02, 2022
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Shares					2,062,500
Exercise Price					$ 11.50
Common Stock Warrants Classified as Liability [Member] | Common Stock Warrant [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5.89			$ 2.21
Common Stock Warrants Classified as Liability [Member] | Common Stock Warrant [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Class of Warrant or Right [Line Items]
Fair Value	$ 249
Issuance Date	Jan. 19, 2022
Exercise Price	$ 5.26
Expiration Date	Mar. 29, 2031
Common Stock Warrants Classified as Liability [Member] | Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Shares		2,062,500			2,062,500
Exercise Price		$ 0.43	$ 1.18		$ 8.82
Common Stock Warrants Classified as Equity [Member] | Common Stock Warrant [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5.89
Common Stock Warrants Classified as Equity [Member] | Common Stock Warrant [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Class of Warrant or Right [Line Items]
Shares	28,517

Warrants - Summary of Estimated

Warrants - Summary of Estimated Fair Value of the Warrants (Details)	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Jun. 30, 2022 $ / shares	Feb. 02, 2022 $ / shares	Jan. 19, 2022 $ / shares
Common Stock Warrant [Member] | Common Stock Warrants Classified as Liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of common stock			$ 2.21		$ 5.89
Warrants, Expected term (in years)			10 years		10 years 6 months
Common Stock Warrant [Member] | Common Stock Warrants Classified As Equity [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of common stock					$ 5.89
Warrants, Expected term (in years)					10 years
Private Placement Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of common stock				$ 11.50
Private Placement Warrants [Member] | Common Stock Warrants Classified as Liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of common stock	$ 0.43	$ 1.18		$ 8.82
Warrants, Expected term (in years)	3 years 9 months	4 years 2 months 1 day		5 years
Risk-free interest rate [Member] | Common Stock Warrant [Member] | Common Stock Warrants Classified as Liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, Measurement input			0.0239		0.0150
Risk-free interest rate [Member] | Common Stock Warrant [Member] | Common Stock Warrants Classified As Equity [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, Measurement input					0.0150
Risk-free interest rate [Member] | Private Placement Warrants [Member] | Common Stock Warrants Classified as Liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, Measurement input	0.0370	0.0405		0.0159
Expected / Implied volatility [Member] | Common Stock Warrant [Member] | Common Stock Warrants Classified as Liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, Measurement input			0.5960		0.5960
Expected / Implied volatility [Member] | Common Stock Warrant [Member] | Common Stock Warrants Classified As Equity [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, Measurement input					0.5960
Expected / Implied volatility [Member] | Private Placement Warrants [Member] | Common Stock Warrants Classified as Liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, Measurement input	0.690	0.690		0.159
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant [Member] | Common Stock Warrants Classified as Liability [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of common stock					$ 5.26

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)	Feb. 02, 2022 $ / shares shares	Mar. 31, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares	Mar. 31, 2022 $ / shares
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, par value (in Dollars per share) | $ / shares		$ 0.0001	$ 0.0001
Common stock, shares issued		151,681,314	151,587,165
Common stock, shares outstanding	122,822,134	151,681,314	151,587,165
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Warrants outstanding		12,383,304	12,383,304
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized		500,000,000	500,000,000
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value (in Dollars per share) | $ / shares		$ 0.0001	$ 0.0001
Legacy Green Light [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares outstanding	104,011,760
Business combination exchange ratio	0.6656
Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Redeemable convertible preferred stock authorized		0	0
Redeemable convertible preferred stock issued		0	0
Redeemable convertible preferred stock outstanding		0	0

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Jan. 01, 2023	Feb. 01, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares subject to vest for additional stock-based compensation recognized			292,650
Share based payment award fair value assumptions grant date modification fair value			$ 2,100
Share-based compensation arrangement by share based payment award modified vesting date			Mar. 31, 2022
Incremental stock based compensation recognizable on event of business combination			$ 1,400
Performance Based Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based payment award fair value assumptions grant date fair value on high level of performance			$ 200
Share based payment award fair value assumptions grant date fair value on non probable outcome					$ 0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of restricted stock vested				$ 25
New GreenLight 2022 Equity and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	6,063,486	31,750,000	14,494,674
Share based compensation arrangement by Share based payment award purchase price of fair market value Common Stock Percent		100%
Share-based compensation arrangement by share-based payment award, percentage of outstanding stock	4%
Award expiration period		10 years
New GreenLight 2022 Equity and Incentive Plan [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of stock options granted			$ 0.56	$ 5.06
Total unrecognized compensation expense not yet recognized			$ 20,300
Share based payment arrangement nonvested award cost not yet recognized period for recognition			2 years 9 months 18 days
Intrinsic value of options exercised			$ 9	$ 600
New GreenLight 2022 Equity and Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		5 years
New GreenLight 2022 Equity and Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		4 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Fair Value Assumptions of Stock Option Awards Estimated on Grant Date (Details) - Stock Option [Member] - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Fair value of underlying common stock	$ 0.56	$ 9.15
Weighted average risk-free interest rate	3.89%	2.56%
Expected term (in years)	6 years 25 days	6 years
Expected volatility	56.97%	56.28%
Expected dividend yield	0%	0%

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Options Activity (Details) - New GreenLight 2022 Equity and Incentive Plan [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Beginning balance, Shares	23,051,188
Shares, Granted	229,500
Shares, Exercised	(94,149)
Shares, Cancelled or forfeited	(755,414)
Ending balance, Shares	22,431,125	23,051,188
Shares, Vested and expected to vest	22,431,125
Shares, Exercisable	11,015,527
Beginning balance, Weighted-Average Exercise Price	$ 2.35
Weighted-Average Exercise Price, Granted	0.97
Weighted-Average Exercise Price, Exercised	0.37
Weighted-Average Exercise Price, Cancelled or forfeited	3.11
Ending balance, Weighted-Average Exercise Price	2.25	$ 2.35
Weighted-Average Exercise Price, Vested and expected to vest	2.25
Weighted-Average Exercise Price, Exercisable	$ 1.11
Weighted-Average Remaining Contractual Term	7 years 7 months 6 days	7 years 9 months 18 days
Weighted-Average Remaining Contractual Term, Vested and expected to vest	7 years 7 months 6 days
Weighted-Average Remaining Contractual Term, Exercisable	6 years 3 months 18 days
Beginning balance, Aggregate Intrinsic Value	$ 7,192
Ending balance, Aggregate Intrinsic Value	355	$ 7,192
Aggregate Intrinsic Value, Vested and expected to vest	355
Aggregate Intrinsic Value, Exercisable	$ 333

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 2,308	$ 2,187
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	1,308	504
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 1,000	$ 1,683

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of the computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net loss	$ (28,469)	$ (38,207)
Denominator:
Weighted-average common stock outstanding, basic	151,614,008	113,558,404
Weighted-average common stock outstanding - diluted	151,614,008	113,558,404
Net loss per share, basic	$ (0.19)	$ (0.34)
Net loss per share, diluted	$ (0.19)	$ (0.34)

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of the excluded potential common stock (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	34,814,429	30,891,334
Unvested Restricted Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		2,664
Options to Purchase Common Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	22,431,125	18,505,366
Common Stock Warrants
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,383,304	12,383,304

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Income Tax Examination [Line Items]
Income tax expense	$ 0	$ 0

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease liabilities, current	$ 4,083		$ 3,358
Operating lease liabilities, noncurrent	48,702		49,569
Right-of-use assets	32,740		$ 32,766	$ 15,200
Operating lease liabilities	52,785			$ 15,900
Unamortized lease incentives					$ 700
Net change in accrued expenses, lease liabilities and other liabilities	(2,718)	$ (9,435)
Cash paid in connection with operating lease liabilities	2,470	2,040
Right-of-use assets obtained in exchange for operating lease liabilities	$ 791	18,100
ASC 842 [Member]
Lessee, Lease, Description [Line Items]
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, immaterial effect	true
Operating lease liabilities, current		6,300
Operating lease liabilities, noncurrent		26,800
Right-of-use assets		31,700
Increase in other non-cash operating lease cost		1,600
Net change in accrued expenses, lease liabilities and other liabilities		1,400
Net change in deferred rent		$ 300

Leases - Schedule of Reconciles

Leases - Schedule of Reconciles the Right of Use Operating and Finance Leases and Corresponding to the Balance Sheet (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Jan. 01, 2022
Assets
Right of use assets - operating lease	$ 32,740	$ 32,766	$ 15,200
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Right of use assets - operating lease	Right of use assets - operating lease
Right of use asset - financing lease	$ 469	$ 519
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net	Property, Plant and Equipment, Net
Total lease assets	$ 33,209	$ 33,285
Current liabilities
Operating lease liabilities, current	$ 4,083	$ 3,358
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Operating lease liabilities, current	Operating lease liabilities, current
Finance lease liabilities, current	$ 134	$ 210
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Long-Term Debt, Noncurrent	Other Long-Term Debt, Noncurrent
Non-Current liabilities
Operating lease liabilities, net of current portion	$ 48,702	$ 49,569
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Operating lease liabilities, net of current portion	Operating lease liabilities, net of current portion
Finance lease liabilities, net of current portion	$ 22	$ 28
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Long-Term Debt, Noncurrent	Other Long-Term Debt, Noncurrent
Total lease liabilities	$ 52,941	$ 53,165

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Operating lease costs	$ 2,498	$ 2,519
Short-term lease costs	8	140
Variable lease costs	764	86
Total operating lease costs	3,270	2,745
Finance lease cost, amortization of right-of-use assets	50	47
Finance lease cost, interest on lease liabilities	3	6
Total finance lease costs	53	53
Total lease costs	$ 3,323	$ 2,798

Leases - Schedule of Other Info

Leases - Schedule of Other Information Related To Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 2,470	$ 2,040
Operating cash flows for finance leases	3	6
Finance cash flows for finance leases	83	160
Right-of-use assets obtained in exchange for operating lease liabilities	$ 791	$ 18,100
Operating Leases
Weighted average remaining lease term (years)	9 years 3 months 29 days	9 years 29 days
Weighted average incremental borrowing rate	11.16%	11.09%
Finance Leases
Weighted average remaining lease term (years)	9 months	1 year 3 months 29 days
Weighted average incremental borrowing rate	7.67%	5.75%

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments Under Non-cancelable Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jan. 01, 2022
Operating Leases
Remainder of 2023	$ 6,828
2024	9,568
2025	8,280
2026	8,204
2027	8,185
Thereafter	46,183
Total future minimum lease payments	87,248
Less: imputed interest	(34,463)
Total	52,785	$ 15,900
Finance Leases
Remainder of 2023	130
2024	32
2025	0
2026	0
2027	0
Thereafter	0
Total future minimum lease payments	162
Less: imputed interest	(6)
Total	$ 156
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherLongTermDebt

Commitments and Contingencies (

Commitments and Contingencies (Details) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Nov. 30, 2021	Dec. 31, 2020
Commitments (Details) [Line Items]
Proceeds from Legal Settlements	$ 0	$ 0
Other Commitment				$ 8.8
License Agreements [Member] | Bayer CropScience LLP [Member] | Maximum [Member]
Commitments (Details) [Line Items]
Milestone payments					$ 2
Other Funding Commitments [Member]
Commitments (Details) [Line Items]
Cost incurred			$ 5.9

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - Mendocino View Farm, LLC [Member] - Farmland Lease Agreement [Member] $ in Millions			3 Months Ended
	Jan. 01, 2024 USD ($)	Jan. 01, 2023 USD ($)	Mar. 31, 2023 USD ($) a
Related Party Transaction [Line Items]
Additional lease rent		$ 0.2
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]
Related Party Transaction [Line Items]
Area of Lease | a			81.25
Operating leases			$ 0.1
Lease, initial term			10 years
Option to Extend			option to extend for an additional ten years
Lease commencement date			Jan. 01, 2023
Lease termination fee			$ 0.2
Additional lease rent			0.4
Allowance on tenant improvement			$ 0.1
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Percentage of ownership			5%
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Forecast [Member]
Related Party Transaction [Line Items]
Additional lease rent	$ 0.2